US20110104276A1 - Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone - Google Patents
Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone Download PDFInfo
- Publication number
- US20110104276A1 US20110104276A1 US12/941,994 US94199410A US2011104276A1 US 20110104276 A1 US20110104276 A1 US 20110104276A1 US 94199410 A US94199410 A US 94199410A US 2011104276 A1 US2011104276 A1 US 2011104276A1
- Authority
- US
- United States
- Prior art keywords
- tablet
- main ingredient
- group
- light
- hydroxypropylcellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 239000004480 active ingredient Substances 0.000 title description 4
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002075 main ingredient Substances 0.000 claims abstract description 50
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 24
- 239000011248 coating agent Substances 0.000 claims abstract description 19
- 238000000576 coating method Methods 0.000 claims abstract description 19
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 17
- 239000011230 binding agent Substances 0.000 claims abstract description 16
- 239000000314 lubricant Substances 0.000 claims abstract description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 26
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 18
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 18
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 18
- 239000004014 plasticizer Substances 0.000 claims description 14
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 13
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 13
- 239000011247 coating layer Substances 0.000 claims description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 12
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 12
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 12
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 12
- 229910052791 calcium Inorganic materials 0.000 claims description 12
- 229950008138 carmellose Drugs 0.000 claims description 12
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 12
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 12
- 239000008101 lactose Substances 0.000 claims description 12
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 12
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 12
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 12
- 239000001069 triethyl citrate Substances 0.000 claims description 12
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 12
- 235000013769 triethyl citrate Nutrition 0.000 claims description 12
- 239000011575 calcium Substances 0.000 claims description 11
- 239000000454 talc Substances 0.000 claims description 8
- 229910052623 talc Inorganic materials 0.000 claims description 8
- 229920002261 Corn starch Polymers 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 235000010980 cellulose Nutrition 0.000 claims description 7
- 239000008120 corn starch Substances 0.000 claims description 7
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 7
- 239000001913 cellulose Substances 0.000 claims description 6
- 239000001087 glyceryl triacetate Substances 0.000 claims description 6
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 6
- 229960002622 triacetin Drugs 0.000 claims description 6
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 3
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 claims description 3
- 235000019658 bitter taste Nutrition 0.000 abstract description 5
- 239000003826 tablet Substances 0.000 description 68
- 229960003073 pirfenidone Drugs 0.000 description 42
- 239000002775 capsule Substances 0.000 description 22
- 239000008186 active pharmaceutical agent Substances 0.000 description 8
- 229940088679 drug related substance Drugs 0.000 description 8
- 239000008187 granular material Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- -1 corn starch Chemical compound 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- CRVGKGJPQYZRPT-UHFFFAOYSA-N diethylamino acetate Chemical compound CCN(CC)OC(C)=O CRVGKGJPQYZRPT-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N o-dicarboxybenzene Natural products OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 125000005624 silicic acid group Chemical class 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
Definitions
- the present invention relates to a tablet containing as the main ingredient 5-methyl-1-phenyl-2-(1H)-pyridone.
- 5-Methyl-1-phenyl-2-(1H)-pyridone is a medicine for pulmonary fibrosis as indication.
- pirfenidone nonproprietary name: pirfenidone
- JP Laid-Open Tokukai
- JP Laid-Open Tokuhyo
- usefulness for treating inflammation in respiratory organs or cutis is described in U.S. Pat. No. 3,974,281, U.S.
- a dosage form of pirfenidone are capsule, tablet, powder, granule, syrup, injection, cream, ointment, insufflation, eye lotion, suppository, and pill, preferable is capsule, injection, cream, and ointment, and working examples are only capsule and ointment.
- a tablet of pirfenidone and its preparation are not described concretely.
- pirfenidone 600 mg to 2400 mg is administrated three times a day in above-mentioned 1).
- capsule containing 800 mg, 1200 mg, and 1600 mg of pirfenidone are described.
- pirfenidone In order to obtain a sufficient therapeutic effect, pirfenidone must be administrated much higher dose in comparison with a usual medicine.
- capsules there are eight types of capsule: No. 000, 00, 0, 1, 2, 3, 4, and 5. The bigger the number is, the smaller the size is.
- the general amount of a medicine contained in each capsule depending on the bulk density or compressibility of the medicine as follows: about 60 mg to 100 mg in No. 5 capsule, about 100 mg to 170 mg in No. 4 capsule, about 140 mg to 220 mg in No. 3 capsule, about 180 mg to 300 mg in No. 2 capsule, about 240 mg to 390 mg in No. 1 capsule and about 340 mg to 540 mg in No. 0 capsule.
- No 2 to No. 4 capsules have often been used for administration to human, a smaller types such as No. 3 to No. 5 capsules are becoming more popular in light of easy administration.
- a capsule usually contains not only an active ingredient, but also a pharmaceutical additive such as excipient, binder, and disintegrator, for improving the stability and efficacy of the active ingredient.
- amount of pirfenidone per one dose is 600 mg as mentioned above
- amount of granules or mixed powder of pirfenidone to be filled in a capsule is about 800 mg to 850 mg.
- amount of granules or mixed powder of pirfenidone to be filled in a capsule is about 800 mg to 850 mg.
- a tablet is readily orally administrated than a capsule.
- the present inventors investigated a formulating of pirfenidone into a tablet which is considered to be effective to improve the compliance in oral administration of a high dose of pirfenidone.
- problems were found such as 1) a characteristic odor or bitterness of pirfenidone, 2) low compressibility of pirfenidone itself, and 3) light-stability.
- the inventors of the present invention have prepared a pirfenidone tablet improved for the compliance, which masks its odor or bitterness, and has the light-stability and rapid dissolution rate, being compact and of sufficient hardness in spite of high content of the main ingredient, whereby accomplished the present invention.
- the present invention relates to the following.
- % disintegrator selected from the group of carmellose calcium, low substituted hydroxypropylcellulose, and cross-linked polyvinylpyrrolidone
- 1 to 10 wt. % binder selected from the group of hydroxypropylcellulose and polyvinylpyrrolidone
- 0.5 to 5 wt. % lubricant selected from the group of magnesium stearate and talc on the main ingredient
- a coating layer containing 2 to 6 wt. % coating basis selected from the group of hydroxypropylmethylcellulose and hydroxypropylcellulose, 0.01 to 1 wt. % plasticizer selected from the group of triethyl citrate and triacetin, and 0.05 to 3 wt.
- a tablet as described in 11 which consists of a plain tablet containing 10 to 50 wt. % lactose, 5 to 40 wt. % carmellose calcium, 1 to 10 wt. % hydroxypropylcellulose, and 0.5 to 5 wt. magnesium stearate on the main ingredient, and a coating layer containing 2 to 6 wt. % hydroxypropylmethylcellulose, 0.01 to 1 wt. % triethyl citrate and 0.05 to 3 wt. % titanium oxide based on the main ingredient.
- excipient means an excipient used in usual pharmaceutical preparations.
- examples of the excipient include silicic acids such as light anhydrous silicic acid, synthetic aluminum silicate, and magnesium aluminometasilicate, inorganic salts such as calcium phosphate, calcium carbonate, and calcium sulfate, sugars such as lactose, sucrose, dextrose, mannitol, and sorbitol, starches such as corn starch, a starch, carboxymethyl starch, celluloses such as crystalline cellulose, and low substituted hydroxypropylcellulose, gum Arabic, dextran, and pullulan. Lactose, corn starch, and crystalline cellulose are more preferable.
- the term “disintegrator” means an additive agent which is used in order to disintegrate and disperse a tablet to minute particles t in the digestive organ.
- the disintegrator include corn starch, carboxymethylcellulose, carboxymethylcellulose calcium, low substituted hydroxypropylcellulose, carmellose sodium, crosscarmellose sodium, carboxymethylstarch sodium, and cross-linked polyvinylpyrrolidone.
- Carmellose calcium, low substituted hydroxypropylcellulose, cross-linked polyvinylpyrrolidone, and the like are more preferable.
- binder means a binder used in usual pharmaceutical preparations.
- examples of the binder include hydroxypropylcellulose, hydroxypropylmethylcellulose, and methylcellulose, polyvinylpyrrolidone. Hydroxypropylcellulose, polyvinylpyrrolidone, and the like are more preferable.
- lubricant are exemplified talc, calcium stearate, sodium stearate, and magnesium stearate. Magnesium stearate, talc, and the like are more preferable.
- coating basis are exemplified sucrose, talc, precipitated calcium carbonate, gelatin, gum Arabic, pullulan, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylacetal diethylaminoacetate, aminoalkyl methacrylate copolymer, cellulose acetate phthalate, methacrylic acid copolymer L, methacrylic acid copolymer LD, methacrylic acid copolymer S, hydroxypropylmethylcellulose phthalate, hydroxymethylpropylmethylcellulose acetate succinate, and carboxymethylethylcellulose. Hydroxypropylmethylcellulose, hydroxypropylcellulose, and the like are more preferable.
- the term “light-shielding agent” means a light-shielding agent used in usual pharmaceutical preparations.
- the light-shielding agent include titanium oxide and ferric oxide. Titanium oxide, and the like are more preferable.
- plasticizer means a plasticizer used in usual pharmaceutical preparations.
- examples of the plasticizer include triethyl citrate, triacetin, glycerin fatty acid ester, and phthalic acid ester. Triethyl citrate, triacetin, and the like are more preferable.
- the present invention tablet is prepared in the following A) to D) processes.
- a mixed powder containing pirfenidone, an excipient, and a disintegrator is granulated by spraying a binder with a fluid bed granulator to give granules.
- a coating solution containing a coating basis, a plasticizer (if necessary), and a light-shielding agent etc. is prepared.
- the target pirfenidone tablet is obtained by coating the pirfenidone plain tablet obtained in B) with the above-mentioned coating solution.
- additives used in a usual solid preparation may be added appropriately.
- the present invention relates to a tablet containing 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and preferable is a 100 to 1000 mg weight of tablet. 150 to 700 mg is more preferable and 240 to 480 mg is the most preferable.
- the amount of the active ingredient is preferably 10 to 85 wt. % the main ingredient to the tablet. 25 to 85 wt. % is more preferable and 50 to 85 wt. % is the most preferable. It is preferable that the content of the main ingredient is 200 mg to 400 mg.
- the designed tablet is more compact, easier to take and contains a more amount of the main ingredient than capsule, thus effectively exhibiting the efficacy.
- the present invention tablet includes a more compact tablet than a capsule containing 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient.
- the present inventors have discovered the problem of light-stability of pirfenidone tablet in the preparation, and found a pirfenidone tablet improving the light-stability with a light-shielding agent. Furthermore, they found preferable are a tablet including 0.05 to 3 wt. % light-shielding agent and a tablet including a light-shielding agent in the coating layer.
- the present invention tablet includes a tablet improving the light-stability and containing 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient.
- Preferable amounts of respective components except the main ingredient in a plain tablet are shown by wt. % to pirfenidone as the main ingredient.
- the amount of the other components is as small as possible because the amount of pirfenidone as the main ingredient is much. But the hardness of a tablet may decrease if the amounts of the other components are too little.
- An excipient is preferably a) 10 to 50 wt. %. b) 15 to 40 wt. % is more preferable. c) 20 to 30 wt. % is the most preferable.
- a disintegrator is preferably d) 5 to 40 wt. %. e) 5 to 25 wt. % is more preferable.
- a binder is preferably g) 1 to 10 wt. %. h) 1 to 7.5 wt. % is more preferable. i) 2 to 5 wt. % is the most preferable.
- a lubricant is preferably j) 0.5 to 5 wt. %. k) 0.5 to 4 wt. % is more preferable. 1) 0.5 to 3 wt. % is the most preferable.
- Preferable amounts of respective components in a coating solution are shown by wt. % to pirfenidone as the main ingredient.
- the components include a coating basis in order to mask a characteristic odor or bitter of pirfenidone, and a light-shielding agent to improve the light-stability, preferably that the amounts of while are as small as possible like the plain tablet.
- a coating basis is preferably m) 2 to 6 wt. %. n) 2 to 5 wt. % is more preferable. o) 2 to 4 wt. % is the most preferable.
- a light-shielding agent is preferably p) 0.05 to 3 wt. %. q) 0.05 to 2 wt. % is more preferable. r) 0.8 to 1.5 wt. % is the most preferable.
- a plasticizer is preferably s) not included or t) 0.05 to 1 wt. % if included.
- the present invention tablet has excellent light-stability as shown in the examples mentioned later. In spite of high content of the main ingredient, the tablet is compact, sufficiently hard and readily administrable.
- the dosage varies with the conditions of the patients, administration route, their age, and body weight. In the case of oral administration, the dosage is thought to be preferable between about 1200 mg to about 1800 mg per a day.
- the amount per one administration is between 400 mg to 600 mg because of three division a day, and it is preferable to take two tablets each containing the main ingredient of between 200 mg to 300 mg.
- Pirfenidone (2,000 g) was mixed with 560 g of lactose and 50 g of carmellose calcium. The mixture was granulated by spraying a 5 (W/W) % aqueous solution of hydroxypropylcellulose (60 g) with a fluid bed granulator. Carmellose calcium and magnesium stearate were added to the granules at the ratios of 5.6 and 1.1 wt. % to the weight of the granules, respectively. The obtained mixture was compressed at a force of 13 kN and to give plain pirfenidone tablets each containing 200 mg of pirfenidone (size: 12.0 ⁇ 6.0 mm, weight: 285 mg/tablet).
- the plain tablets were coated by spraying a 10 wt. % aqueous solution containing hydroxypropylmethylcellulose (66.7 g), triethyl citrate (6.7 g), and titanium oxide 26.6 g in an amount of 10 mg per tablet with a High-coator, to give the objective pirfenidone tablets.
- light irradiation apparatus light stability test apparatus (LTL400-D5) (Nagano Science Equipment Mfg. Co., Ltd.) fluorescent light: D65 fluorescent lamp for color comparing and test temperature and humidity: 25° C., room humidity illumination intensity: 3570 Lx exposure dose: 1,200,000 Lx ⁇ hr coloring difference measure apparatus: Color analyzer TC-1800MK-II measurement method: reflected ray measurement color specification system: CIELAB measurement condition: second degree visual field standard light: C
- Table 2 showed that remarkable color difference was not observed in the case of the pirfenidone drug substance, but a pirfenidone compressed drug substance and a pirfenidone plain tablet have a problem in light-stability. However, a pirfenidone coated tablet solves the problem in light-stability. A pirfenidone coated tablet is confirmed to have no problem in odor or bitterness.
- the present invention provides a compact and sufficiently hard tablet containing a high content of pirfenidone which is necessary to be administered in high dose. And at the same time, the present invention solves the problem of its odor or bitterness and provides a readily administrable tablet. Furthermore, it solves the problem of light-stability caused by tableting pirfenidone and provides the stability requested as a medicine.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent, wherein the odor or bitterness of the 5-methyl-1-phenyl-2-(1H)-pyridone is masked and the light stability is improved.
Description
- The present invention relates to a tablet containing as the main ingredient 5-methyl-1-phenyl-2-(1H)-pyridone.
- 5-Methyl-1-phenyl-2-(1H)-pyridone (nonproprietary name: pirfenidone) is a medicine for pulmonary fibrosis as indication. Various effects of pirfenidone have been reported, for example, 1) treating effect for fibrosis in lung, arteriosclerotic lesion, or the like is described in JP Laid-Open (Tokukai) No. H02-215719, 2) a similar effect to 1) of pirfenidone analogs is described in JP Laid-Open (Tokuhyo) No. H08-510251, 3) usefulness for treating inflammation in respiratory organs or cutis is described in U.S. Pat. No. 3,974,281, U.S. Pat. No. 4,042,699, and U.S. Pat. No. 4,052,509, and 4) inhibiting effect to the synthesis and release of TNF-α is described in JP Laid-Open (Tokuhyo) No. H11-512699.
- In the above-mentioned 1) and 2), exemplified as a dosage form of pirfenidone are capsule, tablet, powder, granule, syrup, injection, cream, ointment, insufflation, eye lotion, suppository, and pill, preferable is capsule, injection, cream, and ointment, and working examples are only capsule and ointment. A tablet of pirfenidone and its preparation are not described concretely.
- With regard to the dosage of pirfenidone, 600 mg to 2400 mg is administrated three times a day in above-mentioned 1). In test example 1 of 2), capsule containing 800 mg, 1200 mg, and 1600 mg of pirfenidone are described. In order to obtain a sufficient therapeutic effect, pirfenidone must be administrated much higher dose in comparison with a usual medicine.
- In general, there are eight types of capsule: No. 000, 00, 0, 1, 2, 3, 4, and 5. The bigger the number is, the smaller the size is. The general amount of a medicine contained in each capsule depending on the bulk density or compressibility of the medicine, as follows: about 60 mg to 100 mg in No. 5 capsule, about 100 mg to 170 mg in No. 4 capsule, about 140 mg to 220 mg in No. 3 capsule, about 180 mg to 300 mg in No. 2 capsule, about 240 mg to 390 mg in No. 1 capsule and about 340 mg to 540 mg in No. 0 capsule. While No 2 to No. 4 capsules have often been used for administration to human, a smaller types such as No. 3 to No. 5 capsules are becoming more popular in light of easy administration. A capsule usually contains not only an active ingredient, but also a pharmaceutical additive such as excipient, binder, and disintegrator, for improving the stability and efficacy of the active ingredient.
- For example, if the amount of pirfenidone per one dose is 600 mg as mentioned above, amount of granules or mixed powder of pirfenidone to be filled in a capsule is about 800 mg to 850 mg. In encapsulating such an amount a No. 000 capsule or two No. 0 capsules are needed, and a patient has a strong pain during the administration. In case of much higher dose, it is impossible to prepare a practical capsule
- In General, a tablet is readily orally administrated than a capsule. The present inventors investigated a formulating of pirfenidone into a tablet which is considered to be effective to improve the compliance in oral administration of a high dose of pirfenidone. In the process, problems were found such as 1) a characteristic odor or bitterness of pirfenidone, 2) low compressibility of pirfenidone itself, and 3) light-stability.
- In the above situation, the inventors of the present invention have prepared a pirfenidone tablet improved for the compliance, which masks its odor or bitterness, and has the light-stability and rapid dissolution rate, being compact and of sufficient hardness in spite of high content of the main ingredient, whereby accomplished the present invention.
- That is, the present invention relates to the following.
- 1) A tablet containing as the main ingredient 5-methyl-1-phenyl-2-(1H)-pyridone.
2) A tablet as described in 1), the weight of which is 100 to 1000 mg.
3) A tablet as described in 1) or 2), which contains 10 to 85 wt. % the main ingredient to the weight of the tablet.
4) A tablet as described in any one of 1) to 3), wherein the content of the main ingredient is 200 mg to 400 mg.
5) A tablet as described in any one of 1) to 4), which contains a light-shielding agent.
6) A tablet as described in 5), which contains a 0.05 to 3 wt. % of the shielding agent based on the main ingredient.
7) A tablet as described in any one of 1) to 4), which contains 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent based on the main ingredient.
8) A tablet as described in 7), which contains 0.01 to 1 wt. % plasticizer based on the main ingredient.
9) A tablet as described in any one of 1) to 4), which consists of a plain tablet containing 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, and 0.5 to 5 wt. % lubricant on the main ingredient, and coating layer containing 2 to 6 wt. % coating basis and 0.05 to 3 wt. % light-shielding agent based on the main ingredient.
10) A tablet as described in 9), which contains 0.01 to 1 wt. % plasticizer based on the main ingredient in a coating layer.
11) A tablet as described in any one of 1) to 4), which consists of a plain tablet containing 10 to 50 wt. % excipient selected from the group of lactose, corn starch, and crystalline cellulose, 5 to 40 wt. % disintegrator selected from the group of carmellose calcium, low substituted hydroxypropylcellulose, and cross-linked polyvinylpyrrolidone, 1 to 10 wt. % binder selected from the group of hydroxypropylcellulose and polyvinylpyrrolidone, and 0.5 to 5 wt. % lubricant selected from the group of magnesium stearate and talc on the main ingredient, and a coating layer containing 2 to 6 wt. % coating basis selected from the group of hydroxypropylmethylcellulose and hydroxypropylcellulose, 0.01 to 1 wt. % plasticizer selected from the group of triethyl citrate and triacetin, and 0.05 to 3 wt. % light-shielding agent selected from the group of titanium oxide and ferric oxide based on the main ingredient.
12) A tablet as described in 11), which consists of a plain tablet containing 10 to 50 wt. % lactose, 5 to 40 wt. % carmellose calcium, 1 to 10 wt. % hydroxypropylcellulose, and 0.5 to 5 wt. magnesium stearate on the main ingredient, and a coating layer containing 2 to 6 wt. % hydroxypropylmethylcellulose, 0.01 to 1 wt. % triethyl citrate and 0.05 to 3 wt. % titanium oxide based on the main ingredient.
13) A tablet as described in any one of 1) to 4), which consists of a plain tablet containing 20 to 30 wt. % excipient selected from the group of lactose, corn starch, and crystalline cellulose, 7.5 to 15 wt. % disintegrator selected from the group of carmellose calcium, low substituted hydroxypropylcellulose, and cross-linked polyvinylpyrrolidone, 2 to 5 wt. % binder selected from the group of hydroxypropylcellulose and polyvinylpyrrolidone, and 0.5 to 3 wt. % lubricant selected from the group of magnesium stearate and talc on the main ingredient, and a coating layer containing 2 to 4 wt. % coating basis selected from the group of hydroxypropylmethylcellulose and hydroxypropylcellulose, 0.01 to 1 wt. % plasticizer selected from the group of triethyl citrate and triacetin, and 0.8 to 3 wt. % titanium oxide as a light-shielding agent based on the main ingredient.
14) A tablet as described in 13), which consists of a plain tablet containing 20 to 30 wt. % lactose, 7.5 to 15 wt. % carmellose calcium, 2 to 5 wt. % hydroxypropylcellulose, and 0.5 to 3 wt. magnesium stearate on the main ingredient, and a coating layer containing 2 to 4 wt. % hydroxypropylmethylcellulose, 0.01 to 1 wt. % triethyl citrate and 0.8 to 3 wt. % titanium oxide based on the main ingredient. - In the present specification, the term “excipient” means an excipient used in usual pharmaceutical preparations. Examples of the excipient include silicic acids such as light anhydrous silicic acid, synthetic aluminum silicate, and magnesium aluminometasilicate, inorganic salts such as calcium phosphate, calcium carbonate, and calcium sulfate, sugars such as lactose, sucrose, dextrose, mannitol, and sorbitol, starches such as corn starch, a starch, carboxymethyl starch, celluloses such as crystalline cellulose, and low substituted hydroxypropylcellulose, gum Arabic, dextran, and pullulan. Lactose, corn starch, and crystalline cellulose are more preferable.
- In the present specification, the term “disintegrator” means an additive agent which is used in order to disintegrate and disperse a tablet to minute particles t in the digestive organ. Examples of the disintegrator include corn starch, carboxymethylcellulose, carboxymethylcellulose calcium, low substituted hydroxypropylcellulose, carmellose sodium, crosscarmellose sodium, carboxymethylstarch sodium, and cross-linked polyvinylpyrrolidone. Carmellose calcium, low substituted hydroxypropylcellulose, cross-linked polyvinylpyrrolidone, and the like are more preferable.
- In the present specification, the term “binder” means a binder used in usual pharmaceutical preparations. Examples of the binder include hydroxypropylcellulose, hydroxypropylmethylcellulose, and methylcellulose, polyvinylpyrrolidone. Hydroxypropylcellulose, polyvinylpyrrolidone, and the like are more preferable.
- In the present specification, as “lubricant” are exemplified talc, calcium stearate, sodium stearate, and magnesium stearate. Magnesium stearate, talc, and the like are more preferable.
- In the present specification, as “coating basis” are exemplified sucrose, talc, precipitated calcium carbonate, gelatin, gum Arabic, pullulan, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylacetal diethylaminoacetate, aminoalkyl methacrylate copolymer, cellulose acetate phthalate, methacrylic acid copolymer L, methacrylic acid copolymer LD, methacrylic acid copolymer S, hydroxypropylmethylcellulose phthalate, hydroxymethylpropylmethylcellulose acetate succinate, and carboxymethylethylcellulose. Hydroxypropylmethylcellulose, hydroxypropylcellulose, and the like are more preferable.
- In the present specification, the term “light-shielding agent” means a light-shielding agent used in usual pharmaceutical preparations. Examples of the light-shielding agent include titanium oxide and ferric oxide. Titanium oxide, and the like are more preferable.
- In the present specification, the term “plasticizer” means a plasticizer used in usual pharmaceutical preparations. Examples of the plasticizer include triethyl citrate, triacetin, glycerin fatty acid ester, and phthalic acid ester. Triethyl citrate, triacetin, and the like are more preferable.
- The present invention tablet is prepared in the following A) to D) processes.
- A) A mixed powder containing pirfenidone, an excipient, and a disintegrator is granulated by spraying a binder with a fluid bed granulator to give granules.
- B) The obtained granules are mixed with a disintegrator, a lubricant, and the like and is compressed at a force of 8 to 18 kN, preferably 11 to 15 kN to give pirfenidone plain tablets.
- C) A coating solution containing a coating basis, a plasticizer (if necessary), and a light-shielding agent etc. is prepared.
- D) The target pirfenidone tablet is obtained by coating the pirfenidone plain tablet obtained in B) with the above-mentioned coating solution.
- In the above-mentioned processes, additives used in a usual solid preparation may be added appropriately.
- The present invention relates to a tablet containing 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and preferable is a 100 to 1000 mg weight of tablet. 150 to 700 mg is more preferable and 240 to 480 mg is the most preferable. The amount of the active ingredient is preferably 10 to 85 wt. % the main ingredient to the tablet. 25 to 85 wt. % is more preferable and 50 to 85 wt. % is the most preferable. It is preferable that the content of the main ingredient is 200 mg to 400 mg.
- The designed tablet is more compact, easier to take and contains a more amount of the main ingredient than capsule, thus effectively exhibiting the efficacy.
- That is, the present invention tablet includes a more compact tablet than a capsule containing 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient.
- Further the present inventors have discovered the problem of light-stability of pirfenidone tablet in the preparation, and found a pirfenidone tablet improving the light-stability with a light-shielding agent. Furthermore, they found preferable are a tablet including 0.05 to 3 wt. % light-shielding agent and a tablet including a light-shielding agent in the coating layer.
- That is, the present invention tablet includes a tablet improving the light-stability and containing 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient.
- Preferable amounts of respective components except the main ingredient in a plain tablet are shown by wt. % to pirfenidone as the main ingredient. In consideration of the compliance, it is preferable that the amount of the other components is as small as possible because the amount of pirfenidone as the main ingredient is much. But the hardness of a tablet may decrease if the amounts of the other components are too little. An excipient is preferably a) 10 to 50 wt. %. b) 15 to 40 wt. % is more preferable. c) 20 to 30 wt. % is the most preferable. A disintegrator is preferably d) 5 to 40 wt. %. e) 5 to 25 wt. % is more preferable. f) 7.5 to 15 wt. % is the most preferable. A binder is preferably g) 1 to 10 wt. %. h) 1 to 7.5 wt. % is more preferable. i) 2 to 5 wt. % is the most preferable. A lubricant is preferably j) 0.5 to 5 wt. %. k) 0.5 to 4 wt. % is more preferable. 1) 0.5 to 3 wt. % is the most preferable.
- Preferable amounts of respective components in a coating solution are shown by wt. % to pirfenidone as the main ingredient. The components include a coating basis in order to mask a characteristic odor or bitter of pirfenidone, and a light-shielding agent to improve the light-stability, preferably that the amounts of while are as small as possible like the plain tablet. A coating basis is preferably m) 2 to 6 wt. %. n) 2 to 5 wt. % is more preferable. o) 2 to 4 wt. % is the most preferable. A light-shielding agent is preferably p) 0.05 to 3 wt. %. q) 0.05 to 2 wt. % is more preferable. r) 0.8 to 1.5 wt. % is the most preferable. A plasticizer is preferably s) not included or t) 0.05 to 1 wt. % if included.
- Preferable amounts of the above-mentioned components to pirfenidone in the present invention tablet are shown as follows. That is, (excipient, disintegrator, binder, lubricant, coating basis, light-shielding agent, plasticizer)=(a, d, g, j, m, p, s), (a, d, g, j, m, p, t), (a, d, g, j, m, q, s), (a, d, g, j, m, q, t), (a, d, g, j, m, r, s), (a, d, g, j, m, r, t), (a, d, g, j, n, p, s), (a, d, g, j, n, p, t), (a, d, g, j, n, q, s), (a, d, g, j, n, q, t), (a, d, g, j, n, r, s), (a, d, g, j, n, r, t), (a, d, g, j, o, p, s), (a, d, g, j, o, p, t), (a, d, g, j, o, q, s), (a, d, g, j, o, q, t), (a, d, g, j, o, r, s), (a, d, g, j, o, r, t), (a, d, g, k, m, p, s), (a, d, g, k, m, p, t), (a, d, g, k, m, q, s), (a, d, g, k, m, q, t), (a, d, g, k, m, r, s), (a, d, g, k, m, r, t), (a, d, g, k, n, p, s), (a, d, g, k, n, p, t), (a, d, g, k, n, q, s), (a, d, g, k, n, q, t), (a, d, g, k, n, r, s), (a, d, g, k, n, r, t), (a, d, g, k, o, p, s), (a, d, g, k, o, p, t), (a, d, g, k, o, q, s), (a, d, g, k, o, q, t), (a, d, g, k, o, r, s), (a, d, g, k, o, r, t), (a, d, g, k, m, p, s), (a, d, g, k, m, p, t), (a, d, g, k, m, q, s), (a, d, g, k, m, q, t), (a, d, g, k, m, r, s), (a, d, g, k, m, r, (a, d, g, j, n, p, s), (a, d, g, j, n, p, t), (a, d, g, j, n, q, s), (a, d, g, j, n, q, t), (a, d, g, j, n, r, s), (a, d, g, j, n, r, t), (a, d, g, l, o, p, s), (a, d, g, l, o, p, t), (a, d, g, l, o, q, s), (a, d, g, l, o, q, t), (a, d, g, l, o, r, s), (a, d, g, l, o, r, t), (a, d, h, j, m, p, s), (a, d, h, j, m, p, t), (a, d, h, j, m, q, s), (a, d, h, j, m, q, t), (a, d, h, j, m, r, s), (a, d, h, j, m, r, t), (a, d, h, j, n, p, s), (a, d, h, j, n, p, t), (a, d, h, j, n, q, s), (a, d, h, j, n, q, t), (a, d, h, j, n, r, s), (a, d, h, j, n, r, t), (a, d, h, j, o, p, s), (a, d, h, j, o, p, t), (a, d, h, j, o, q, s), (a, d, h, j, o, q, t), (a, d, h, j, o, r, s), (a, d, h, j, o, r, t), (a, d, h, k, m, p, s), (a, d, h, k, m, p, t), (a, d, h, k, m, q, s), (a, d, h, k, m, q, t), (a, d, h, k, m, r, s), (a, d, h, k, m, r, t), (a, d, h, k, n, p, s), (a, d, h, k, n, p, t), (a, d, h, k, n, q, s), (a, d, h, k, n, q, t), (a, d, h, k, n, r, s), (a, d, h, k, n, r, t), (a, d, h, k, o, p, s), (a, d, h, k, o, p, t), (a, d, h, k, o, q, s), (a, d, h, k, o, q, t), (a, d, h, k, o, r, s), (a, d, h, k, o, r, t), (a, d, h, k, m, p, s), (a, d, h, k, m, p, t), (a, d, h, k, m, q, s), (a, d, h, k, m, q, t), (a, d, h, k, m, r, s), (a, d, h, k, m, r, t), (a, d, h, l, n, p, s) (a, d, h, l, n, p, t), (a, d, h, l, n, q, s), (a, d, h, l, n, q, t), (a, d, h, l, n, r, s), (a, d, h, l, n, r, t), (a, d, h, l, o, p, s), (a, d, h, l, o, p, t), (a, d, h, l, o, q, s), (a, d, h, l, o, q, t), (a, d, h, l, o, r, s), (a, d, h, l, o, r, t), (a, d, i, j, m, p, s), (a, d, i, j, m, p, t), (a, d, i, j, m, q, s), (a, d, i, j, m, q, t), (a, d, i, j, m, r, s), (a, d, i, j, m, r, t), (a, d, i, j, n, p, s), (a, d, i, j, n, p, t), (a, d, i, j, n, q, s), (a, d, i, j, n, q, t), (a, d, i, j, n, r, s), (a, d, i, j, n, r, t), (a, d, i, j, o, p, s), (a, d, i, j, o, p, t), (a, d, j, o, q, s), (a, d, q, t), (a, d, i, j, o, r, s), (a, d, j, o, r, t), (a, d, i, l, m, p, s), (a, d, i, l, m, p, t), (a, d, i, l, m, q, s), (a, d, i, l, m, q, t), (a, d, i, l, m, r, s), (a, d, i, l, m, r, t), (a, d, i, l, n, p, s), (a, d, i, l, n, p, t), (a, d, k, n, q, s), (a, d, i, l, n, q, t), (a, d, i, l, n, r, s), (a, d, i, l, n, r, t), (a, d, i, k, o, p, s), (a, d, i, k, o, p, t), (a, d, i, k, o, q, s), (a, d, i, k, o, q, t), (a, d, i, k, o, r, s), (a, d, k, o, r, t), (a, d, i, l, m, p, s), (a, d, i, l, m, p, t), (a, d, i, l, m, q, s), (a, d, i, l, m, q, t), (a, d, i, l, m, r, s), (a, d, i, l, m, r, t), (a, d, i, l, n, p, s), (a, d, i, l, n, p, t), (a, d, i, l, n, q, s), (a, d, i, l, n, q, t), (a, d, i, l, n, r, s), (a, d, i, l, n, r, t), (a, d, i, k, o, p, s), (a, d, i, k, o, p, t), (a, d, i, l, o, q, s), (a, d, i, l, o, q, t), (a, d, i, k, o, r, s), (a, d, i, l, o, r, t), (a, e, g, j, m, p, s), (a, e, g, j, m, p, t), (a, e, g, j, m, q, s), (a, e, g, j, m, q, t), (a, e, g, j, m, r, s), (a, e, g, j, m, r, t), (a, e, g, j, n, p, s), (a, e, g, p, t), (a, e, g, j, n, q, s), (a, e, g, j, n, q, t), (a, e, g, j, n, r, s), (a, e, g, j, n, r, t), (a, e, g, j, o, p, s), (a, e, g, j, o, p, t), (a, e, g, j, o, q, s), (a, e, g, j, o, q, t), (a, e, g, j, o, r, s), (a, e, g, j, o, r, t), (a, e, g, k, m, p, s), (a, e, g, k, m, p, t), (a, e, g, k, m, q, s), (a, e, g, k, m, q, t), (a, e, g, k, m, r, s), (a, e, g, k, m, r, t), (a, e, g, k, n, p, s), (a, e, g, k, n, p, t), (a, e, g, k, n, q, s), (a, e, g, k, n, q, t), (a, e, g, k, n, r, s), (a, e, g, k, n, r, t), (a, e, g, k, o, p, s), (a, e, g, k, o, p, t), (a, e, g, k, o, q, s), (a, e, g, k, o, q, t), (a, e, g, k, o, r, s), (a, e, g, k, o, r, t), (a, e, g, k, m, p, s), (a, e, g, k, m, p, t), (a, e, g, k, m, q, s), (a, e, g, k, m, q, t), (a, e, g, j, m, r, s), (a, e, g, j, m, r, t), (a, e, g, l, n, p, s), (a, e, g, j, n, p, t), (a, e, g, j, n, q, s), (a, e, g, j, n, q, t), (a, e, g, j, n, r, s), (a, e, g, l, r, t), (a, e, g, l, o, p, s), (a, e, g, l, o, p, t), (a, e, g, l, o, q, s), (g, l, o, q, t), (a, e, g, l, o, r, s), (a, e, g, l, o, r, t), (a, e, h, j, m, p, s), (a, e, h, j, m, p, t), (a, e, h, j, m, q, s), (a, e, h, j, m, q, t), (, e, h, j, m, r, s), (a, e, h, j, m, r, t), (a, e, h, j, n, p, s), (a, e, h, j, n, p, t), (a, e, h, j, n, q, s), (a, e, h, j, n, q, t), (a, e, h, j, n, r, s), (a, e, h, j, n, r, t), (a, e, h, j, o, p, s), (a, e, h, j, o, p, t), (a, e, h, j, o, q, s), (a, e, h, j, o, q, t), (a, h, j, o, r, s), (a, e, h, j, o, r, t), (a, e, h, k, m, p, s), (a, e, h, k, m, p, t), (a, e, h, k, m, q, s), (a, e, h, k, q, t), (a, e, h, k, m, r, s), (a, e, h, k, m, r, t), (a, e, h, k, n, p, s), (a, e, h, k, n, p, t), (a, e, h, k, n, q, s), (a, e, h, k, n, q, t), (a, e, h, k, n, r, s), (a, e, h, k, n, r, t), (a, e, h, k, o, p, s), (a, e, h, k, o, p, t), (a, e, h, k, o, q, s), (a, e, h, k, o, q, t), (a, e, h, k, o, r, s), (a, e, h, k, o, r, t), (a, e, h, l, m, p, s), (a, e, h, k, m, p, t), (a, e, h, k, m, q, s), (a, e, h, k, m, q, t), (a, e, h, k, m, r, s), (a, e, h, k, m, r, t), (a, e, h, l, n, p, s), (a, e, h, l, n, p, t), (a, e, h, l, n, q, s), (a, e, h, l, n, q, t), (a, e, h, l, n, r, s), (a, e, h, l, n, r, t), (a, e, h, l, o, p, s), (a, e, h, l, o, p, t), (a, h, l, o, q, s), (a, e, h, l, o, q, t), (a, e, h, l, o, r, s), (a, e, h, l, o, r, t), (a, e, i, j, m, p, s), (a, e, i, j, m, p, t), (a, e, i, j, m, q, s), (a, e, i, j, m, q, t), (a, e, i, j, m, r, s), (a, e, j, m, r, t), (a, e, i, j, n, p, s), (a, e, i, j, n, p, t), (a, e, i, j, n, q, s), (a, e, i, j, n, q, t), (a, e, i, j, n, r, s), (a, e, i, j, n, r, t), (a, e, i, j, o, p, s), (a, e, i, j, o, p, t), (a, e, i, j, o, q, s), (a, e, i, j, o, q, t), (a, e, i, j, o, r, s), (a, e, i, j, o, r, t), (a, e, i, l, m, p, s), (a, e, k, m, p, t), (a, e, i, l, m, q, s), (a, e, i, l, m, q, t), (a, e, i, l, m, r, s), (a, e, i, l, m, r, t), (a, e, i, l, n, p, s), (a, e, i, l, n, p, t), (a, e, i, l, n, q, s), (a, e, i, l, n, q, t), (a, e, k, n, r, s), (a, e, i, l, n, r, t), (a, e, i, k, o, p, s), (a, e, i, k, o, p, t), (a, e, i, k, o, q, s), (a, e, i, k, o, q, t), (a, e, i, k, o, r, s), (a, e, i, k, o, r, t), (a, e, i, l, m, p, s), (a, e, i, l, m, p, t), (a, e, i, l, m, q, s), (a, e, i, k, m, q, t), (a, e, i, l, m, r, s), (a, e, i, l, m, r, t), (a, e, i, l, n, p, s), (a, e, i, l, n, p, t), (a, e, i, l, n, q, s), (a, e, i, l, n, q, t), (a, e, i, l, n, r, s), (a, e, i, l, n, r, t), (a, e, i, l, o, p, s), (a, e, i, l, o, p, t), (a, e, i, l, o, q, s), (a, e, i, k, o, q, t), (a, e, i, k, o, r, s), (a, e, i, k, o, r, t), (a, f, g, j, m, p, s), (a, f, g, j, m, p, t), (a, f, g, j, m, q, s), (a, f, g, j, m, q, t), (a, f, g, j, r, s), (a, g, g, j, m, r, t), (a, f, g, j, n, p, s), (a, f, g, j, n, p, t), (a, f, g, j, n, q, s), (a, f, g, j, n, q, t), (a, f, g, j, n, r, s), (a, f, g, j, n, r, t), (a, f, g, j, o, p, s), (a, f, g, j, o, p, t), (a, f, g, j, o, q, s), (a, f, g, j, o, q, t), (a, f, g, j, o, r, s), (a, f, g, j, o, r, t), (a, f, g, k, m, p, s), (a, f, g, k, m, p, t), (a, f, g, k, m, q, s), (a, f, g, k, m, q, t), (a, f, g, k, m, r, s), (a, f, g, k, m, r, t), (a, f, g, k, n, p, s), (a, f, g, k, n, p, t), (a, f, g, k, n, q, s), (a, f, g, k, n, q, t), (a, f, g, k, n, r, s), (a, f, g, k, n, r, t), (a, f, g, k, o, p, s), (a, f, g, k, o, p, t), (a, f, g, k, o, q, s), (a, f, g, k, o, q, t), (a, f, g, k, o, r, s), (a, f, g, k, o, r, t), (a, f, g, k, m, p, s), (a, f, g, k, m, p, t), (a, f, g, l, m, q, s), (a, f, g, k, m, q, t), (a, f, g, k, m, r, s), (a, f, g, k, m, r, (a, f, g, j, n, p, s), (a, f, g, j, n, p, t), (a, f, g, j, n, q, s), (a, f, g, j, n, q, t), (a, f, g, j, n, r, s), (a, f, g, j, n, t), (a, f, g, l, o, p, s), (a, f, g, l, o, p, t), (a, f, g, l, o, q, s), (a, f, g, l, o, q, t), (a, f, g, l, o, r, s), (a, f, g, l, o, r, t), (a, f, h, j, m, p, s), (a, f, h, j, m, p, t), (a, f, h, j, m, q, s), (a, f, h, j, m, q, t), (a, f, h, j, m, r, s), (a, f, h, j, m, r, t), (a, f, h, j, n, p, s), (a, f, h, j, n, p, t), (a, f, h, j, n, q, s), (a, f, h, j, n, q, t), (a, f, h, j, n, r, s), (a, f, h, j, n, r, t), (a, f, h, j, o, p, s), (a, f, h, j, o, p, t), (a, f, h, j, o, q, s), (a, f, h, j, o, q, t), (a, f, h, j, o, r, s), (a, f, h, j, o, r, t), (a, f, h, k, m, p, s), (a, f, h, k, m, p, t), (a, f, h, k, m, q, s), (a, f, h, k, m, q, t), (a, f, h, k, m, r, s), (a, f, h, k, m, r, t), (a, f, h, k, n, p, s), (a, f, h, k, n, p, t), (a, f, h, k, n, q, s), (a, f, h, k, n, q, t), (a, f, h, k, n, r, s), (a, f, h, k, n, r, t), (a, f, h, k, o, p, s), (a, f, h, k, o, p, t), (a, f, h, k, o, q, s), (a, f, h, k, o, q, t), (a, f, h, k, o, r, s), (a, f, h, k, o, r, t), (a, f, h, k, m, p, s), (a, f, h, k, m, p, t), (a, f, h, k, m, q, s), (a, f, h, l, m, q, t), (a, f, h, k, m, r, s), (a, f, h, k, m, r, t), (a, f, h, l, n, p, s), (a, f, h, l, n, p, t), (a, f, h, l, n, q, s), (a, f, h, l, n, q, t), (a, f, h, l, n, r, s), (a, f, h, l, n, r, t), (a, f, h, l, o, p, s), (a, f, h, l, o, p, t), (a, f, h, l, o, q, s), (a, f, h, l, o, q, t), (a, f, h, l, o, r, s), (a, f, h, l, o, r, t), (a, f, i, j, m, p, s), (a, f, i, j, m, p, t), (a, f, i, j, m, q, s), (a, f, i, j, m, q, t), (a, f, i, j, m, r, s), (a, f, i, j, m, r, t), (a, f, i, j, n, p, s), (a, j, i, j, n, p, t), (a, f, i, j, n, q, s), (a, f, i, j, n, q, t), (a, f, i, j, n, r, s), (a, f, i, j, n, r, t), (a, f, i, j, o, p, s), (a, f, i, j, o, p, t), (a, f, i, j, o, q, s), (a, f, i, j, o, q, t), (a, f, i, j, o, r, s), (a, f, i, j, o, r, t), (a, f, i, k, m, p, s), (a, f, i, k, m, p, t), (a, f, i, k, m, q, s), (a, f, i, k, m, q, t), (a, f, i, k, m, r, s), (a, f, i, k, m, r, t), (a, f, i, k, n, p, s), (a, f, i, k, n, p, t), (a, f, i, k, n, q, s), (a, f, i, k, n, q, t), (a, f, i, l, n, r, s), (a, f, i, l, n, r, t), (a, f, i, k, o, p, s), (a, f, i, k, o, p, t), (a, f, i, k, o, q, s), (a, f, i, k, o, q, t), (a, f, i, k, o, r, s), (a, f, i, k, o, r, t), (a, f, i, l, m, p, s), (a, f, i, l, m, p, t), (a, f, i, l, m, q, s), (a, f, i, l, m, q, t), (a, f, i, l, m, r, s), (a, f, i, l, m, r, t), (a, f, i, l, n, p, s), (a, f, i, l, n, p, t), (a, f, i, l, n, q, s), (a, f, i, l, n, q, t), (a, f, i, l, n, r, s), (a, f, i, l, n, r, t), (a, f, i, l, o, p, s), (a, f, i, l, o, p, t), (a, f, i, l, o, q, s), (a, f, i, l, o, q, t), (a, f, i, l, o, r, s), (a, f, i, l, o, r, t), (b, d, g, j, m, p, s), (b, d, g, j, m, p, t), (b, d, g, j, m, q, s), (b, d, g, j, m, q, t), (b, d, g, j, m, r, s), (b, d, g, j, m, r, t), (b, d, g, j, n, p, s), (b, d, g, j, n, p, t), (b, d, g, j, n, q, s), (b, d, g, j, n, q, t), (b, d, g, j, n, r, s), (b, d, g, j, n, r, t), (b, d, g, j, o, p, s), (b, d, g, j, o, p, t), (b, d, g, j, o, q, s), (b, d, g, j, o, q, t), (b, d, g, j, o, r, s), (b, d, g, j, o, r, t), (b, d, g, k, m, p, s), (b, d, g, k, m, p, t), (b, d, g, k, m, q, s), (b, d, g, k, m, q, t), (b, d, g, k, m, r, s), (b, d, g, k, m, r, t), (b, d, g, k, n, p, s), (b, d, g, k, n, p, t), (b, d, g, k, n, q, s), (b, d, g, k, n, q, t), (b, d, g, k, r, s), (b, d, g, k, n, r, (b, d, g, k, o, p, s), (b, d, g, k, o, p, t), (b, d, g, k, o, q, s), (b, d, g, k, o, q, t), (b, d, g, k, o, r, s), (b, d, g, k, o, r, t), (b, d, g, k, m, p, s), (b, d, g, l, m, p, t), (b, d, g, l, m, q, s), (b, d, g, l, m, q, t), (b, d, g, l, m, r, s), (b, d, g, l, m, r, t), (b, d, g, l, n, p, s), (b, d, g, l, n, p, t), (b, d, g, l, n, q, s), (b, d, g, l, n, q, t), (b, d, g, l, n, r, s), (b, d, g, l, n, r, t), (b, d, g, l, o, p, s), (b, d, g, l, o, p, t), (b, d, g, l, o, q, s), (b, d, g, l, o, q, t), (b, d, g, l, o, r, s), (b, d, g, l, o, r, t), (b, d, h, j, m, p, s), (b, d, h, j, m, p, t), (b, d, h, j, m, q, s), (b, d, h, j, m, q, t), (b, d, h, j, m, r, s), (b, d, h, j, m, r, t), (b, d, h, j, n, p, s), (b, d, h, j, n, p, t), (b, d, h, j, n, q, s), (b, d, h, j, n, q, t), (b, d, h, j, n, r, s), (b, d, h, j, n, r, t), (b, d, h, j, o, p, s), (b, d, h, j, o, p, t), (b, d, h, j, o, q, s), (b, d, h, l, o, q, t), (b, d, h, l, o, r, s), (b, d, h, l, o, r, t), (b, d, h, j, m, p, s), (b, d, h, j, m, p, t), (b, d, h, j, m, q, s), (b, d, h, j, m, q, t), (b, d, h, j, m, r, s), (b, d, h, j, k, m, r, t), (b, d, h, k, n, p, s), (b, d, h, k, n, p, t), (b, d, h, k, n, q, s), (b, d, h, k, n, q, t), (b, d, h, k, n, r, s), (b, d, h, k, n, r, t), (b, d, h, k, o, p, s), (b, d, h, k, o, p, t), (b, d, h, k, o, q, s), (b, d, h, k, o, q, t), (b, d, h, k, o, r, s), (b, d, h, k, o, r, t), (b, d, h, l, m, p, s), (b, d, h, l, m, p, t), (b, d, h, l, m, q, s), (b, d, h, l, m, q, t), (b, d, h, l, m, r, s), (b, d, h, l, m, r, t), (b, d, h, l, n, p, s), (b, d, h, l, n, p, t), (b, d, h, l, n, q, s), (b, d, h, l, n, q, t), (b, d, h, l, n, r, s), (b, d, h, l, n, r, t), (b, d, h, l, o, p, s), (b, d, h, l, o, p, t), (b, d, h, l, o, q, s), (b, d, h, l, o, q, t), (b, d, h, l, o, r, s), (b, d, h, l, o, r, t), (b, d, i, j, m, p, s), (b, d, i, j, m, p, t), (b, d, i, j, m, q, s), (b, d, i, j, m, q, t), (b, d, i, j, m, r, s), (b, d, i, j, m, r, t), (b, d, i, j, n, p, s), (b, d, i, j, n, p, t), (b, d, i, j, n, q, s), (b, d, n, q, t), (b, d, i, j, n, r, s), (b, d, 1, j, n, r, t), (b, d, i, j, o, p, s), (b, d, i, j, o, p, t), (b, d, i, j, o, q, s), (b, d, i, j, o, q, t), d, i, j, o, r, s), (b, d, i, j, o, r, t), (b, d, i, l, m, p, t), (b, d, i, k, m, p, t), (b, d, i, k, m, q, s), (b, d, i, k, m, q, t), (b, d, i, k, r, s), (b, d, i, k, m, r, t), (b, d, i, k, n, p, s), (b, d, i, k, n, p, t), (b, d, i, k, n, q, s), (b, d, i, k, n, q, t), (b, d, i, k, n, r, s), (b, d, i, k, n, r, t), (b, d, i, k, o, p, s), (b, d, i, k, o, p, t), (b, d, i, k, o, q, s), (b, d, i, k, o, q, t), (b, d, i, k, o, r, s), (b, d, i, k, o, r, t), (b, d, i, l, m, p, s), (b, d, i, l, m, p, t), (b, d, i, l, m, q, s), (b, d, i, l, m, q, t), (b, d, i, l, m, r, s), (b, d, i, l, m, r, t), (b, d, i, l, n, p, s), (b, d, i, l, n, p, t), (b, d, i, l, n, q, s), (b, d, i, l, n, q, t), (b, d, i, l, n, r, s), (b, d, i, l, n, r, t), (b, d, i, l, o, p, s), (b, d, i, l, o, p, t), (b, d, i, l, o, q, s), (b, d, i, l, o, q, t), (b, d, i, l, o, r, s), (b, d, i, l, o, r, t), (b, e, g, j, m, p, s), (b, e, g, j, m, p, t), (b, e, g, j, m, q, s), (b, e, g, j, m, q, t), (b, e, g, j, m, r, s), (b, e, g, j, m, r, t), (b, e, g, j, n, p, s), (b, e, g, j, n, p, t), (b, e, g, j, n, q, s), (b, e, g, j, n, q, t), (b, e, g, j, n, r, s), (b, e, g, j, n, r, t), (b, e, g, j, o, p, s), (b, e, g, j, o, p, t), (b, e, g, j, o, q, s), (b, e, g, j, o, q, t), (b, e, g, j, o, r, s), (b, e, g, j, o, r, t), (b, e, g, k, m, p, s), (b, e, g, k, m, p, t), (b, e, g, k, m, q, s), (b, e, g, k, m, q, t), (b, e, g, k, m, r, s), (b, e, g, k, m, r, t), (b, e, g, k, n, p, s), (b, e, g, k, n, p, t), (b, e, g, k, n, q, s), (b, e, g, k, n, q, t), (b, e, g, k, n, r, s), (b, e, g, k, n, r, t), (b, e, g, k, o, p, s), (b, e, g, k, o, p, t), (b, e, g, k, o, q, s), (b, e, g, k, o, q, t), (b, e, g, k, o, r, s), (b, e, g, k, o, r, t), (b, e, g, k, m, p, s), (b, e, g, l, m, p, t), (b, e, g, l, m, q, s), (b, e, g, l, m, q, t), (b, e, g, l, m, r, s), (b, e, g, l, m, r, t), (b, e, g, l, n, p, s), (b, e, g, l, n, p, t), (b, e, g, l, n, q, s), (b, e, g, l, n, q, t), (b, e, g, l, n, r, s), (b, e, g, l, n, r, t), (b, e, g, l, o, p, s), (b, e, g, l, o, p, t), (b, e, g, l, o, q, s), (b, e, g, l, o, q, t), (b, e, g, l, o, r, s), (b, e, g, l, o, r, t), (b, e, h, j, m, p, s), (b, e, h, j, m, p, t), (b, h, j, m, q, s), (b, e, h, j, m, q, t), (b, e, h, j, m, r, s), (b, e, h, j, m, r, t), (b, e, h, j, n, p, s), (b, e, h, j, n, p, t), (b, e, h, j, n, q, s), (b, e, h, j, n, q, t), (b, e, h, j, n, r, s), (b, e, h, j, n, r, t), (b, e, h, j, o, p, s), (b, e, h, j, o, p, t), (b, e, h, j, o, q, s), (b, e, h, j, o, q, t), (b, e, h, j, o, r, s), (b, e, h, j, o, r, t), (b, h, k, m, p, s), (b, e, h, k, m, p, t), (b, h, k, m, q, s), (b, h, k, m, q, t), (b, e, h, k, m, r, s), (b, e, h, k, m, r, t), (b, e, h, k, n, p, s), (b, e, h, k, n, p, t), (b, e, h, k, n, q, s), (b, e, h, k, n, q, t), (b, e, h, k, n, r, s), (b, e, h, k, n, r, t), (b, h, k, o, p, s), (b, e, h, k, o, p, t), (b, e, h, k, o, q, s), (b, e, h, k, o, q, t), (b, e, h, k, o, r, s), (b, e, h, k, o, r, (b, e, h, k, m, p, s), (b, e, h, l, m, p, t), (b, e, h, l, m, q, s), (b, e, h, l, m, q, t), (b, e, h, l, m, r, s), (b, e, h, l, m, t), (b, e, h, l, n, p, s), (b, e, h, l, n, p, t), (b, e, h, l, n, q, s), (b, e, h, l, n, q, t), (b, e, h, l, n, r, s), (b, e, h, l, n, r, t), (b, e, h, l, o, p, s), (b, e, h, l, o, p, t), (b, e, h, l, o, q, s), (b, e, h, l, o, q, t), (b, e, h, l, o, r, s), (b, e, h, l, o, r, t), (b, e, i, j, m, p, s), (b, e, i, j, m, p, t), (b, e, i, j, m, q, s), (b, e, i, j, m, q, t), (b, e, i, j, m, r, s), (b, e, i, j, m, r, t), (b, e, i, j, n, p, s), (b, e, i, j, n, p, t), (b, e, i, j, n, q, s), (b, e, i, j, n, q, t), (b, e, i, j, n, r, s), (b, e, i, j, n, r, t), (b, e, i, j, o, p, s), (b, e, i, j, o, p, t), (b, e, i, j, o, q, s), (b, j, o, q, t), (b, e, i, j, o, r, s), (b, e, i, j, o, r, t), (b, e, i, l, m, p, s), (b, e, i, l, m, p, t), (b, e, i, l, m, q, s), (b, e, i, l, m, q, t), (b, e, i, l, m, r, s), (b, e, i, l, m, r, t), (b, e, k, n, p, s), (b, e, i, k, n, p, t), (b, e, i, k, n, q, s), (b, e, i, k, n, q, t), (b, e, i, k, n, r, s), (b, e, i, k, n, r, t), (b, e, i, k, o, p, s), (b, e, i, k, o, p, t), (b, e, i, k, o, q, s), (b, e, i, k, o, q, t), (b, e, i, k, o, r, s), (b, e, i, k, o, r, t), (b, e, i, l, m, p, s), (b, e, i, l, m, p, t), (b, e, i, l, m, q, s), (b, e, i, l, m, q, t), (b, e, i, l, m, r, s), (b, e, i, l, m, r, t), (b, e, i, l, n, p, s), (b, e, i, l, n, p, t), (b, e, i, l, n, q, s), (b, e, i, l, n, q, t), (b, e, i, l, n, r, s), (b, e, i, l, n, r, t), (b, e, i, l, o, p, s), (b, e, i, l, o, p, t), (b, e, i, l, o, q, s), (b, e, i, l, o, q, t), (b, e, i, l, o, r, s), (b, e, i, l, o, r, t), (b, f, g, j, m, p, s), (b, f, g, j, m, p, t), (b, f, g, j, m, q, s), (b, f, g, j, m, q, t), (b, f, g, j, m, r, s), (b, f, g, j, m, r, t), (b, f, g, j, n, p, s), (b, f, g, j, n, p, t), (b, f, g, j, n, q, s), (b, f, g, j, n, q, t), (b, f, g, j, n, r, s), (b, f, g, j, n, r, t), (b, f, g, j, o, p, s), (b, f, g, j, o, p, t), (b, f, g, j, o, q, s), (b, f, g, j, o, q, t), (b, f, g, j, o, r, s), (b, f, g, j, o, r, t), (b, f, g, k, m, p, s), (b, f, g, k, m, p, t), (b, f, g, k, m, q, s), (b, f, g, k, m, q, t), (b, f, g, k, m, r, s), (b, f, g, k, m, r, t), (b, f, g, k, n, p, s), (b, f, g, k, p, t), (b, f, g, k, n, q, s), (b, f, g, k, n, q, t), (b, f, g, k, n, r, s), (b, f, g, k, n, r, t), (b, f, g, k, o, p, s), (b, f, g, k, o, p, t), (b, f, g, k, o, q, s), (b, f, g, k, q, t), (b, f, g, k, o, r, s), (b, f, g, k, o, r, t), (b, f, g, l, m, p, s), (b, f, g, l, m, p, t), (b, f, g, l, m, q, s), (b, f, g, l, m, q, t), (b, f, g, l, m, r, s), (b, f, g, l, m, r, t), (b, f, g, l, n, p, s), (b, f, g, l, n, p, t), (b, f, g, l, n, q, s), (b, f, g, l, n, q, t), (b, f, g, l, n, r, s), (b, f, g, l, n, r, t), (b, f, g, l, o, p, s), (b, f, g, l, o, p, t), (b, f, l, o, q, s), (b, f, g, l, o, q, t), (b, f, g, l, o, r, s), (b, f, g, l, o, r, t), (b, f, h, j, p, s), (b, f, h, j, m, p, t), (b, f, h, j, m, q, s), (b, f, h, j, m, q, t), (b, f, h, j, m, r, s), (b, f, h, j, m, r, t), (b, f, h, j, n, p, s), (b, f, h, j, n, p, t), (b, f, h, j, n, q, s), (b, f, h, j, n, q, t), (b, f, h, j, n, r, s), (b, f, h, j, n, r, t), (b, f, h, j, o, p, s), (b, f, h, j, o, p, t), (b, f, h, j, o, q, s), (b, f, h, j, o, q, t), (b, f, h, j, o, r, s), (b, f, h, j, o, r, t), (b, f, h, k, m, p, s), (b, f, h, k, m, p, t), (b, f, h, k, m, q, s), (b, f, h, k, m, q, t), (b, f, h, k, m, r, s), (b, f, h, k, m, r, t), (b, f, h, k, n, p, s), (b, f, h, k, n, p, t), (b, f, h, k, n, q, s), (b, f, h, k, n, q, t), (b, f, h, k, n, r, s), (b, f, h, k, n, r, t), (b, f, h, k, o, p, s), (b, f, h, k, o, p, t), (b, f, h, k, o, q, s), (b, f, h, k, o, q, t), (b, f, h, k, o, r, s), (b, f, h, k, o, r, t), (b, f, h, l, m, p, s), (b, f, h, l, m, p, t), (b, f, h, l, m, q, s), (b, f, h, l, m, q, t), (b, f, h, l, m, r, s), (b, f, h, l, m, r, t), (b, f, h, l, n, p, s), (b, f, h, l, n, p, t), (b, f, h, l, n, q, s), (b, f, h, l, n, q, t), (b, f, h, l, n, r, s), (b, f, h, l, n, r, t), (b, f, h, l, o, p, s), (b, f, h, l, o, p, t), (b, f, h, l, o, q, s), (b, f, h, l, o, q, t), (b, f, h, l, o, r, s), (b, f, h, l, or, t), (b, f, i, j, m, p, s), (b, f, i, j, m, p, t), (b, f, i, j, m, q, s), (b, f, i, j, m, q, t), (b, f, i, j, m, r, s), (b, f, i, j, m, r, t), (b, f, i, j, n, p, s), (b, f, i, j, n, p, t), (b, f, i, j, n, q, s), (b, f, i, j, n, q, t), (b, f, i, j, n, r, s), (b, f, i, j, n, r, t), (b, f, i, j, o, p, s), (b, f, i, j, o, p, t), (b, f, t, j, o, q, s), (b, f, i, j, o, q, t), (b, f, i, j, o, r, s), (b, f, i, j, o, r, t), (b, f, i, l, m, p, s), (b, f, i, l, m, p, t), (b, f, i, l, m, q, s), (b, f, i, l, m, q, t), (b, f, i, k, m, r, s), (b, f, i, k, m, r, t), (b, f, i, k, n, p, s), (b, f, i, k, n, p, t), (b, f, i, k, n, q, s), (b, f, i, k, n, q, t), (b, f, i, k, n, r, s), (b, f, i, k, n, r, t), (b, f, i, k, o, p, s), (b, f, i, k, o, p, t), (b, f, i, k, o, q, s), (b, f, i, k, o, q, t), (b, f, i, k, o, r, s), (b, f, i, k, o, r, t), (b, f, i, l, m, p, s), (b, f, i, l, m, p, t), (b, f, i, l, m, q, s), (b, f, m, q, t), (b, f, i, l, m, r, s), (b, f, i, l, m, r, t), (b, f, i, l, n, p, s), (b, f, i, l, n, p, t), (b, f, i, l, n, q, s), (b, f, i, l, n, q, t), (b, f, i, l, n, r, s), (b, f, i, l, n, r, t), (b, f, i, l, o, p, s), (b, f, i, l, o, p, t), (b, f, i, l, o, q, s), (b, f, i, l, o, q, t), (b, f, i, l, o, r, s), (b, f, i, l, o, r, t), (c, d, g, j, m, p, s), (c, d, g, j, m, p, t), (c, d, g, j, m, q, s), (c, d, g, j, m, q, t), (c, d, g, j, m, r, s), (c, d, g, j, m, r, t), (c, d, g, j, n, p, s), (c, d, g, j, n, p, t), (c, d, g, j, n, q, s), (c, d, g, j, n, q, t), (c, d, g, j, n, r, s), (c, d, g, j, n, r, t), (c, d, g, j, o, p, s), (c, g, j, o, p, t), (c, d, g, j, o, q, s), (c, d, g, j, o, q, t), (c, d, g, j, o, r, s), (c, d, g, j, o, r, t), (c, d, g, k, m, p, s), (c, d, g, k, m, p, t), (c, d, g, k, m, q, s), (c, d, g, k, m, q, t), (c, d, g, k, m, r, s), (c, d, g, k, m, r, t), (c, d, g, k, n, p, s), (c, d, g, k, n, p, t), (c, d, g, k, n, q, s), (c, d, g, k, n, q, t), (c, d, g, k, n, r, s), (c, d, g, k, n, r, t), (c, d, g, k, o, p, s), (c, d, g, k, o, p, t), (c, d, g, k, o, q, s), (c, d, g, k, o, q, t), (c, d, g, k, o, r, s), (c, d, g, k, o, r, t), (c, d, g, l, m, p, s), (c, d, g, l, m, p, t), (c, d, g, l, m, q, s), (c, d, g, l, m, q, t), (c, d, g, l, m, r, s), (c, d, g, k, m, r, t), (c, d, g, j, n, p, s), (c, d, g, j, n, p, t), (c, d, g, j, n, q, s), (c, d, g, j, n, q, t), (c, d, g, j, n, r, s), (c, d, g, j, n, r, t), (c, d, g, l, o, p, s), (c, d, g, l, o, p, t), (c, d, g, l, o, q, s), (c, d, g, l, o, q, t), (c, d, g, l, o, r, s), (c, d, g, l, o, r, t), (c, d, h, j, m, p, s), (c, d, h, j, m, p, t), (c, d, h, j, q, s), (c, d, h, j, m, q, t), (c, d, h, j, m, r, s), (c, d, h, j, m, r, t), (c, d, h, j, n, p, s), (c, d, h, j, n, p, t), (c, d, h, j, n, q, s), (c, d, h, j, n, q, t), (c, d, h, j, n, r, s), (c, d, h, j, n, r, t), (c, d, h, j, o, p, s), (c, d, h, j, o, p, t), (c, d, h, j, o, q, s), (c, d, h, j, o, q, t), (c, d, h, j, o, r, s), (c, d, h, j, o, r, t), (c, d, h, k, m, p, s), (c, d, h, k, m, p, t), (c, d, h, k, m, q, s), (c, d, h, k, m, q, t), (c, d, h, k, m, r, s), (c, d, h, k, m, r, t), (c, d, h, k, n, p, s), (c, d, h, k, n, p, t), (c, d, h, k, n, q, s), (c, d, h, k, n, q, t), (c, d, h, k, n, r, s), (c, d, h, k, n, r, t), (c, d, h, k, o, p, s), (c, d, h, k, o, p, t), (c, d, h, k, o, q, s), (c, d, h, k, o, q, t), (c, d, h, k, o, r, s), (c, d, h, k, o, r, t), (c, d, h, l, m, p, s), (c, d, h, l, m, p, t), (c, d, h, l, m, q, s), (c, d, h, l, m, q, t), (c, d, h, l, m, r, s), (c, d, h, l, m, r, t), (c, d, h, l, n, p, s), (c, d, h, l, n, p, t), (c, d, h, l, n, q, s), (c, d, h, l, n, q, t), (c, d, h, l, n, r, s), (c, d, h, l, n, r, t), (c, d, h, l, o, p, s), (c, d, h, l, o, p, t), (c, d, h, l, o, q, s), (c, d, h, l, o, q, t), (c, d, h, l, o, r, s), (c, d, h, l, o, r, t), (c, d, i, j, m, p, s), (c, d, i, j, m, p, t), (c, d, i, j, m, q, s), (c, d, i, j, m, q, t), (c, d, r, j, m, r, s), (c, d, i, j, m, r, t), (c, d, i, j, n, p, s), (c, d, i, j, n, p, t), (c, d, i, j, n, q, s), (c, d, i, j, n, q, t), (c, d, i, j, n, r, s), (c, d, i, j, n, r, t), (c, d, i, j, o, p, s), (c, d, i, j, o, p, t), (c, d, j, o, q, s), (c, d, j, o, q, t), (c, d, i j, o, r, s), (c, d, j, o, r, t), (c, d, k, m, p, s), (c, d, i, k, m, p, t), (c, d, i, k, m, q, s), (c, d, i, k, m, q, t), (c, d, i, k, m, r, s), (c, d, k, m, r, t), (c, d, i, k, n, p, s), (c, d, i, k, n, p, t), (c, d, i, k, n, q, s), (c, d, i, k, n, q, t), (c, d, i, k, n, r, s), (c, d, i, k, n, r, t), (c, d, i, k, o, p, s), (c, d, i, k, o, p, t), (c, d, i, k, o, q, s), (c, d, i, k, o, q, t), (c, d, i k, o, r, s), (c, d, i, k, o, r, t), (c, d, i, l, m, p, s), (c, d, i, l, m, p, t), (c, d, i, l, m, q, s), (c, d, i, l, m, q, t), (c, d, i, l, m, r, s), (c, d, i, l, m, r, t), (c, d, i, l, n, p, s), (c, d, i, l, n, p, t), (c, d, i, l, n, q, s), (c, d, i, l, n, q, t), (c, d, i, l, n, r, s), (e, d, i, l, n, r, t), (c, d, i, k, o, p, s), (c, d, i, k, o, p, t), (c, d, i, k, o, q, s), (c, d, i, l, o, q, t), (c, d, i, l, o, r, s), (c, d, i, l, o, r, t), (c, e, g, j, m, p, s), (c, e, g, j, m, p, t), (c, e, g, j, m, q, s), (c, e, g, j, m, q, t), (c, e, g, j, m, r, s), (c, e, g, j, m, r, t), (c, e, g, j, n, p, s), (c, e, g, j, n, p, t), (c, e, g, j, n, q, s), (c, e, g, j, n, q, t), (c, e, g, j, n, r, s), (c, e, g, j, n, r, t), (c, e, g, j, o, p, s), (c, e, g, j, o, p, t), (e, e, g, j, o, q, s), (c, e, g, j, o, q, t), (c, e, g, j, o, r, s), (c, e, g, j, o, r, t), (c, e, g, k, m, p, s), (c, e, g, k, m, p, t), (c, e, g, k, m, q, s), (c, e, g, k, m, q, t), (c, e, g, k, m, r, s), (c, e, g, k, m, r, t), (c, e, g, k, n, p, s), (c, g, k, n, p, t), (c, e, g, k, n, q, s), (c, e, g, k, n, q, t), (c, g, k, n, r, s), (c, e, g, k, n, r, t), (c, e, g, k, o, p, s), (c, e, g, k, o, p, t), (c, e, g, k, o, q, s), (c, e, g, k, o, q, t), (c, e, g, k, o, r, s), (c, e, g, k, o, r, t), (c, e, g, l, m, p, s), (c, e, g, l, m, p, t), (c, e, g, l, m, q, s), (c, e, g, k, m, q, t), (c, e, g, l, m, r, s), (c, e, g, k, m, r, t), (c, e, g, l, n, p, s), (c, e, g, l, n, p, t), (c, e, g, l, n, q, s), (c, e, g, l, n, q, t), (c, e, g, l, n, r, s), (c, e, g, l, n, r, t), (c, e, g, l, o, p, s), (c, e, g, l, o, p, t), (c, e, g, l, o, q, s), (c, e, g, l, o, q, t), (c, e, g, l, o, r, s), (c, e, g, l, o, r, t), (c, e, h, j, m, p, s), (c, e, h, j, m, p, t), (c, e, h, j, m, q, s), (c, h, j, m, q, t), (c, e, h, j, m, r, s), (c, e, h, j, m, r, t), (c, e, h, j, n, p, s), (c, e, h, j, n, p, t), (c, e, h, j, n, q, s), (c, e, h, j, n, q, t), (c, e, h, j, n, r, s), (c, e, h, j, n, r, t), (c, e, h, j, o, p, s), (c, e, h, j, o, p, t), (c, e, h, j, o, q, s), (c, e, h, j, o, q, t), (c, e, h, j, o, r, s), (c, e, h, j, o, r, (c, e, h, k, m, p, s), (c, e, h, k, m, p, t), (c, e, h, k, m, q, s), (c, e, h, k, m, q, t), (c, e, h, k, m, r, s), (c, e, h, k, m, r, t), (c, e, h, k, n, p, s), (c, e, h, k, n, p, t), (c, e, h, k, n, q, s), (c, e, h, k, n, q, t), (c, e, h, k, n, r, s), (c, e, h, k, n, r, t), (c, e, h, k, o, p, s), (c, e, h, k, o, p, t), (c, e, h, k, o, q, s), (c, e, h, k, o, q, t), (c, e, h, k, o, r, s), (c, e, h, k, o, r, t), (c, e, h, k, m, p, s), (c, e, h, k, m, p, t), (c, e, h, l, m, q, s), (c, e, h, l, m, q, t), (c, e, h, l, m, r, s), (c, h, l, m, r, t), (c, e, h, l, n, p, s), (c, e, h, l, n, p, t), (c, e, h, l, n, q, s), (c, e, h, l, n, q, t), (c, e, h, l, n, r, s), (c, e, h, l, n, r, t), (c, e, h, l, o, p, s), (c, e, h, l, o, p, t), (c, e, h, l, o, q, s), (c, e, h, l, o, q, t), (c, e, h, l, o, r, s), (c, e, h, l, o, r, t), (c, e, i, j, m, p, s), (c, e, i, j, p, t), (c, e, i, j, m, q, s), (c, e, i, j, m, q, t), (c, e, i, j, m, r, s), (c, e, i, j, m, r, t), (c, e, i, j, n, p, s), (c, e, i, j, n, p, t), (c, e, i, j, n, q, s), (c, e, i, j, n, q, t), (c, e, i, j, n, r, s), (c, e, i, j, n, r, t), (c, e, i, j, p, s), (c, e, i, j, o, p, t), (c, e, i, j, o, q, s), (c, e, i, j, o, q, t), (c, e, i, j, o, r, s), (c, e, i, j, o, r, t), (c, e, i, k, m, p, s), (c, e, i, k, m, p, t), (c, e, i, k, m, q, s), (c, e, i, k, m, q, t), (c, e, i, k, m, r, s), (c, e, i, k, m, r, t), (c, e, i, k, n, p, s), (c, e, i, k, n, p, t), (c, e, i, k, n, q, s), (c, e, i, k, n, q, t), (c, e, i, k, n, r, s), (c, e, i, k, n, r, t), (c, e, i, k, o, p, s), (c, e, i, k, o, p, t), (c, e, i, k, o, q, s), (c, e, i, k, o, q, t), (c, e, i, k, o, r, s), (c, e, i, k, o, r, t), (c, e, i, l, m, p, s), (c, e, i, l, m, p, t), (c, e, i, l, m, q, s), (c, e, i, m, q, t), (c, e, l, m, r, s), (c, e, i, l, m, r, t), (c, e, i, l, n, p, s), (c, e, i, l, n, p, t), (c, e, i, l, n, q, s), (c, e, i, l, n, q, t), (c, e, i, l, n, r, s), (c, e, i, l, n, r, t), (c, e, i, l, o, p, s), (c, e, i, l, o, p, t), (c, e, i, l, o, q, s), (c, e, i, l, o, q, t), (c, e, i, l, o, r, s), (c, e, i, l, o, r, t), (c, f, g, j, m, p, s), (c, f, g, j, m, p, t), (c, f, g, j, m, q, s), (c, f, g, j, m, q, t), (c, f, g, j, m, r, s), (c, f, g, j, m, r, t), (c, f, g, j, n, p, s), (c, f, g, j, n, p, t), (c, f, g, j, n, q, s), (c, f, g, j, n, q, t), (c, f, g, j, n, r, s), (c, f, g, j, n, r, t), (c, f, g, j, o, p, s), (c, f, g, j, o, p, t), (c, f, g, j, o, q, s), (c, f, g, j, o, q, t), (c, f, g, j, o, r, s), (c, f, g, j, o, r, t), (c, f, g, k, m, p, s), (c, f, g, k, m, p, t), (c, f, g, k, m, q, s), (c, f, g, k, m, q, t), (c, f, g, k, m, r, s), (c, f, g, k, m, r, t), (c, f, g, k, n, p, s), (c, f, g, k, n, p, t), (c, f, g, k, n, q, s), (c, f, g, k, n, q, t), (c, f, g, k, n, r, s), (c, f, g, k, n, r, t), (c, f, g, k, o, p, s), (c, g, k, o, p, t), (c, f, g, k, o, q, s), (c, f, g, k, o, q, t), (c, f, g, k, o, r, s), (c, f, g, k, o, r, t), (c, f, g, l, m, p, s), (c, f, g, l, m, p, t), (c, f, g, l, m, q, s), (c, f, g, l, m, q, t), (c, f, g, l, m, r, s), (c, f, g, l, m, r, t), (c, f, g, l, n, p, s), (c, f, g, l, n, p, t), (c, f, g, l, n, q, s), (c, f, g, l, n, q, t), (c, f, g, l, n, r, s), (c, f, g, l, r, t), (c, f, g, l, o, p, s), (c, f, g, l, o, p, t), (c, f, g, l, o, q, s), (c, g, l, o, q, t), (c, f, g, l, o, r, s), (c, f, g, l, o, r, t), (c, h, j, m, p, s), (c, f, h, j, p, t), (c, f, h, j, m, q, s), (c, f, h, j, m, q, t), (c, f, h, j, m, s), (c, f, h, j, m, r, t), (c, f, h, j, n, p, s), (c, f, h, j, n, p, t), (c, f, h, j, n, q, s), (c, f, h, j, n, q, t), (c, f, h, j, n, r, s), (c, f, h, j, n, r, t), (c, f, h, j, o, p, s), (c, f, h, j, o, p, t), (c, f, h, j, o, q, s), (c, f, h, j, o, q, t), (c, f, h, j, o, r, s), (c, f, h, j, o, r, t), (c, f, h, k, m, p, s), (c, f, h, k, m, p, t), (c, f, h, k, m, q, s), (c, f, h, k, m, q, t), (c, f, h, k, m, r, s), (c, f, h, k, m, r, t), (c, f, h, k, n, p, s), (c, f, h, k, n, p, t), (c, f, h, k, n, q, s), (c, f, h, k, n, q, t), (c, f, h, k, n, r, s), (c, f, h, k, n, r, t), (c, f, h, k, o, p, s), (c, f, h, k, o, p, t), (c, f, h, k, o, q, s), (c, f, h, k, o, q, t), (c, f, h, k, o, r, s), (c, f, h, k, o, r, t), (c, f, h, k, m, p, s), (c, f, h, l, m, p, t), (c, f, h, l, m, q, s), (c, f, h, l, m, q, t), (c, f, h, l, m, r, s), (c, f, h, l, m, r, t), (c, f, h, l, n, p, s), (c, f, h, l, n, p, t), (c, f, h, l, n, q, s), (c, f, h, l, n, q, t), (c, f, h, l, n, r, s), (c, f, h, l, n, r, t), (c, f, h, l, o, p, s), (c, f, h, l, o, p, t), (c, f, h, l, o, q, s), (c, f, h, l, o, q, t), (c, f, h, l, o, r, s), (c, f, h, l, o, r, t), (c, f, i, j, m, p, s), (c, f, i, j, m, p, t), (c, f, i, j, m, q, s), (c, f, i, j, m, q, t), (c, f, i, j, m, r, s), (c, f, i, j, m, r, t), (c, f, i, j, n, p, s), (c, f, i, j, n, p, t), (c, f, i, j, n, q, s), (c, f, i, j, n, q, t), (c, f, i, j, n, r, s), (c, f, i, j, n, r, t), (c, f, i, j, o, p, s), (c, f, i, j, o, p, t), (c, f, i, j, o, q, s), (c, f, i, j, o, q, t), (c, f, i, j, o, r, s), (c, f, i, j, o, r, t), (c, f, i, k, m, p, s), (c, f, i, k, m, p, t), (c, f, i, k, m, q, s), (c, f, i, k, m, q, t), (c, f, r, k, m, r, s), (c, f, r, k, m, r, t), (c, f, r, k, n, p, s), (c, f, i, k, n, p, t), (c, f, i, k, n, q, s), (c, f, i, k, n, q, t), (c, f, i, k, n, r, s), (c, f, i, k, n, r, t), (c, f, i, k, o, p, s), (c, f, i, k, o, p, t), (c, f, i, k, o, q, s), (c, f, i, k, o, q, t), (c, f, k, o, r, s), (c, f, i, k, o, r, t), (c, f, i, l, m, p, s), (c, f, i, l, m, p, t), (c, f, i, l, m, q, s), (c, f, i, l, m, q, t), (c, f, i, l, m, r, s), (e, f, i, l, m, r, t), (c, f, i, l, n, p, s), (c, f, i, l, n, p, t), (c, f, i, l, n, q, s), (c, f, i, l, n, q, t), (c, f, i, l, n, r, s), (c, f, i, l, n, r, t), (c, f, l, o, p, s), (c, f, i, l, o, p, t), (c, f, i, l, o, q, s), (c, f, i, l, o, q, t), (c, f, i, l, o, r, s), (c, f, i, l, o, r, t).
- The present invention tablet has excellent light-stability as shown in the examples mentioned later. In spite of high content of the main ingredient, the tablet is compact, sufficiently hard and readily administrable.
- The dosage varies with the conditions of the patients, administration route, their age, and body weight. In the case of oral administration, the dosage is thought to be preferable between about 1200 mg to about 1800 mg per a day. The amount per one administration is between 400 mg to 600 mg because of three division a day, and it is preferable to take two tablets each containing the main ingredient of between 200 mg to 300 mg.
- The following examples and test examples are provided to further illustrate the present invention and are not to be construed as limiting the scope thereof.
- Pirfenidone (2,000 g) was mixed with 560 g of lactose and 50 g of carmellose calcium. The mixture was granulated by spraying a 5 (W/W) % aqueous solution of hydroxypropylcellulose (60 g) with a fluid bed granulator. Carmellose calcium and magnesium stearate were added to the granules at the ratios of 5.6 and 1.1 wt. % to the weight of the granules, respectively. The obtained mixture was compressed at a force of 13 kN and to give plain pirfenidone tablets each containing 200 mg of pirfenidone (size: 12.0×6.0 mm, weight: 285 mg/tablet).
- The plain tablets were coated by spraying a 10 wt. % aqueous solution containing hydroxypropylmethylcellulose (66.7 g), triethyl citrate (6.7 g), and titanium oxide 26.6 g in an amount of 10 mg per tablet with a High-coator, to give the objective pirfenidone tablets.
- The components of a pirfenidone tablet is shown below.
-
TABLE 1 Component Amount Note Pirfenidone 200.0 mg Lactose 56.0 mg Carmellose calcium 20.0 mg Intra-granular: 5.0 mg Extera-granular 15.0 mg Hydroxypropylcellulose 6.0 mg Magnesium stearate 3.0 mg Total of weight of a plain tablet 285.0 mg Hydroxypropylmethylcellulose 2910 6.67 mg Titanium oxide 2.66 mg Triethyl citrate 0.67 mg Magnesium stearate trace 0.02 mg Talc trace 0.02 mg Total weight of coating 10.00 mg Total weight of a coated tablet 295.0 mg - Light exposure test of pirfenidone was carried out under the following condition, using “drug substance” obtained by packing 500 mg of milled pirfenidone drug substance in a heat-sealed transparent SP (Striped Package), “compressed drug substance” obtained by statically compressing 300 mg of milled pirfenidone drug substance, “the plain tablets” obtained in the above Example 1, and “the coated tablets” obtained in the above Example 1. The results are shown in table 2.
- light irradiation apparatus: light stability test apparatus (LTL400-D5) (Nagano Science Equipment Mfg. Co., Ltd.)
fluorescent light: D65 fluorescent lamp for color comparing and test
temperature and humidity: 25° C., room humidity
illumination intensity: 3570 Lx
exposure dose: 1,200,000 Lx·hr
coloring difference measure apparatus: Color analyzer TC-1800MK-II
measurement method: reflected ray measurement
color specification system: CIELAB
measurement condition: second degree visual field
standard light: C -
TABLE 2 Color difference Sample (ΔE) Discoloration Drug substance 0.73 slight Compressed drug substance 3.62 remarkable Plain tablets 5.08 remarkable Coated tablets 0.75 slight - Table 2 showed that remarkable color difference was not observed in the case of the pirfenidone drug substance, but a pirfenidone compressed drug substance and a pirfenidone plain tablet have a problem in light-stability. However, a pirfenidone coated tablet solves the problem in light-stability. A pirfenidone coated tablet is confirmed to have no problem in odor or bitterness.
- The present invention provides a compact and sufficiently hard tablet containing a high content of pirfenidone which is necessary to be administered in high dose. And at the same time, the present invention solves the problem of its odor or bitterness and provides a readily administrable tablet. Furthermore, it solves the problem of light-stability caused by tableting pirfenidone and provides the stability requested as a medicine.
Claims (14)
1. A tablet containing as the main ingredient 5-methyl-1-phenyl-2-(1H)-pyridone.
2. A tablet as claimed in claim 1 , the weight of which is 100 to 1000 mg.
3. A tablet as claimed in claim 1 , which contains 10 to 85 wt. % main ingredient to the weight of the tablet.
4. A tablet as claimed in claim 1 , wherein the content of the main ingredient is 200 mg to 400 mg.
5. A tablet as claimed in claim 1 , which contains a light-shielding agent.
6. A tablet as claimed in claim 5 , which contains 0.05 to 3 wt. % shielding agent based on the main ingredient.
7. A tablet as claimed in claim 1 , which contains 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt % coating basis, and 0.05 to 3 wt. % light-shielding agent based on the main ingredient.
8. A tablet as claimed in claim 7 , which contains 0.01 to 1 wt. % plasticizer based on the main ingredient.
9. A tablet as claimed in claim 1 , which consists of a plain tablet containing 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, and 0.5 to 5 wt. % lubricant on the main ingredient, and coating layer containing 2 to 6 wt. % coating basis and 0.05 to 3 wt. % light-shielding agent based on the main ingredient.
10. A tablet as claimed in claim 9 , which contains 0.01 to 1 wt. % plasticizer based on the main ingredient in a coating layer.
11. A tablet as claimed in claim 1 , which consists of a plain tablet containing 10 to 50 wt. % excipient selected from the group of lactose, corn starch, and crystalline cellulose, 5 to 40 wt. % disintegrator selected from the group of carmellose calcium, low substituted hydroxypropylcellulose, and cross-linked polyvinylpyrrolidone, 1 to 10 wt. % binder selected from the group of hydroxypropylcellulose and polyvinylpyrrolidone, and 0.5 to 5 wt. % lubricant selected from the group of magnesium stearate and talc on the main ingredient, and a coating layer containing 2 to 6 wt. % coating basis selected from the group of hydroxypropylmethylcellulose and hydroxypropylcellulose, 0.01 to 1 wt. % plasticizer selected from the group of triethyl citrate and triacetin, and 0.05 to 3 wt. % light-shielding agent selected from the group of titanium oxide and ferric oxide based on the main ingredient.
12. A tablet as claimed in claim 11 , which consists of a plain tablet containing 10 to 50 wt. % lactose, 5 to 40 wt. % carmellose calcium, 1 to 10 wt % hydroxypropylcellulose, and 0.5 to 5 wt. magnesium stearate on the main ingredient, and a coating layer containing 2 to 6 wt. % hydroxypropylmethylcellulose, 0.01 to 1 wt. % triethyl citrate and 0.05 to 3 wt. % titanium oxide based on the main ingredient.
13. A tablet as claimed in claim 1 , which consists of a plain tablet containing 20 to 30 wt. % excipient selected from the group of lactose, corn starch, and crystalline cellulose, 7.5 to 15 wt. % disintegrator selected from the group of carmellose calcium, low substituted hydroxypropylcellulose, and cross-linked polyvinylpyrrolidone, 2 to 5 wt. % binder selected from the group of hydroxypropylcellulose and polyvinylpyrrolidone, and 0.5 to 3 wt. % lubricant selected from the group of magnesium stearate and talc on the main ingredient, and a coating layer containing 2 to 4 wt. % coating basis selected from the group of hydroxypropylmethylcellulose and hydroxypropylcellulose, 0.01 to 1 wt. % plasticizer selected from the group of triethyl citrate and triacetin, and 0.8 to 3 wt. % titanium oxide as a light-shielding agent based on the main ingredient.
14. A tablet as claimed in claim 13 , which consists of a plain tablet containing 20 to 30 wt % lactose, 7.5 to 15 wt. % carmellose calcium, 2 to 5 wt. % hydroxypropylcellulose, and 0.5 to 3 wt. magnesium stearate on the main ingredient, and a coating layer containing 2 to 4 wt. % hydroxypropylmethylcellulose, 0.01 to 1 wt. % triethyl citrate and 0.8 to 3 wt. % titanium oxide based on the main ingredient.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/941,994 US20110104276A1 (en) | 2001-01-29 | 2010-11-08 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone |
US13/333,142 US20120183615A1 (en) | 2001-01-29 | 2011-12-21 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone |
US13/662,221 US9017722B2 (en) | 2001-01-29 | 2012-10-26 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
US14/671,251 US20150209341A1 (en) | 2001-01-29 | 2015-03-27 | Pharmaceutical composition containing as an active ingredient 5-methyl -1-phenyl-2-(1h)-pyridone |
US14/951,313 US9561217B2 (en) | 2001-01-29 | 2015-11-24 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
US15/385,451 US20170100380A1 (en) | 2001-01-29 | 2016-12-20 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-19393 | 2001-01-29 | ||
JP2001019393 | 2001-01-29 | ||
PCT/JP2002/000544 WO2002060446A1 (en) | 2001-01-29 | 2002-01-25 | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
US10/470,334 US7867516B2 (en) | 2001-01-29 | 2002-01-25 | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
US12/941,994 US20110104276A1 (en) | 2001-01-29 | 2010-11-08 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/470,334 Continuation US7867516B2 (en) | 2001-01-29 | 2002-01-25 | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
PCT/JP2002/000544 Continuation WO2002060446A1 (en) | 2001-01-29 | 2002-01-25 | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
US10470334 Continuation | 2002-01-25 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/333,142 Continuation US20120183615A1 (en) | 2001-01-29 | 2011-12-21 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110104276A1 true US20110104276A1 (en) | 2011-05-05 |
Family
ID=18885277
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/470,334 Expired - Lifetime US7867516B2 (en) | 2001-01-29 | 2002-01-25 | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
US12/941,994 Abandoned US20110104276A1 (en) | 2001-01-29 | 2010-11-08 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone |
US13/333,142 Abandoned US20120183615A1 (en) | 2001-01-29 | 2011-12-21 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone |
US13/662,221 Expired - Fee Related US9017722B2 (en) | 2001-01-29 | 2012-10-26 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
US14/671,251 Abandoned US20150209341A1 (en) | 2001-01-29 | 2015-03-27 | Pharmaceutical composition containing as an active ingredient 5-methyl -1-phenyl-2-(1h)-pyridone |
US14/951,313 Expired - Fee Related US9561217B2 (en) | 2001-01-29 | 2015-11-24 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
US15/385,451 Abandoned US20170100380A1 (en) | 2001-01-29 | 2016-12-20 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/470,334 Expired - Lifetime US7867516B2 (en) | 2001-01-29 | 2002-01-25 | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/333,142 Abandoned US20120183615A1 (en) | 2001-01-29 | 2011-12-21 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone |
US13/662,221 Expired - Fee Related US9017722B2 (en) | 2001-01-29 | 2012-10-26 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
US14/671,251 Abandoned US20150209341A1 (en) | 2001-01-29 | 2015-03-27 | Pharmaceutical composition containing as an active ingredient 5-methyl -1-phenyl-2-(1h)-pyridone |
US14/951,313 Expired - Fee Related US9561217B2 (en) | 2001-01-29 | 2015-11-24 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
US15/385,451 Abandoned US20170100380A1 (en) | 2001-01-29 | 2016-12-20 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone |
Country Status (8)
Country | Link |
---|---|
US (7) | US7867516B2 (en) |
EP (1) | EP1356816B1 (en) |
JP (1) | JP4077320B2 (en) |
KR (2) | KR100777169B1 (en) |
AT (1) | ATE452637T1 (en) |
DE (1) | DE60234812D1 (en) |
TW (1) | TWI314868B (en) |
WO (1) | WO2002060446A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8753679B2 (en) | 2005-09-22 | 2014-06-17 | Intermune, Inc. | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
US9561217B2 (en) | 2001-01-29 | 2017-02-07 | Intermune, Inc. | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
US10188637B2 (en) | 2016-03-29 | 2019-01-29 | Hoffmann-La Roche Inc. | Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070154550A1 (en) * | 2003-08-28 | 2007-07-05 | Potdar Arti | Pharmaceutical composition comprising anticonvulsant with taste mask coating |
JP2005187339A (en) * | 2003-12-24 | 2005-07-14 | Iwaki Seiyaku Co Ltd | Light-resistant terbinafine hydrochloride film-coated tablets |
ES2524922T3 (en) | 2005-05-10 | 2014-12-15 | Intermune, Inc. | Pyridone derivatives to modulate the stress-activated protein kinase system |
US20070203202A1 (en) * | 2005-12-02 | 2007-08-30 | Robinson Cynthia Y | Methods of reducing adverse events associated with pirfenidone therapy |
ES2395396T3 (en) * | 2006-12-18 | 2013-02-12 | Intermune, Inc. | Method for providing a pirfenidone therapy to a patient |
US20080287508A1 (en) * | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
JP5248040B2 (en) | 2007-05-25 | 2013-07-31 | リードケミカル株式会社 | Patch containing 5-methyl-1-phenyl-2- (1H) -pyridone |
MX2007009796A (en) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel containing pirfenidone. |
US8304413B2 (en) | 2008-06-03 | 2012-11-06 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
JP2010120912A (en) | 2008-11-21 | 2010-06-03 | Lead Chemical Co Ltd | Adhesive skin patch containing 5-methyl-1-phenyl-2-(1h)-pyridone |
KR20210009441A (en) | 2009-04-01 | 2021-01-26 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
US20100256194A1 (en) * | 2009-04-01 | 2010-10-07 | Bial - Portela & Ca, S.A. | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same |
CN101972236A (en) * | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | Sustained release preparation containing pirfenidone |
US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
AU2012212269B2 (en) | 2011-01-31 | 2016-05-19 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
MX2011007675A (en) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Process for manufacturing a pharmaceutical composition in a sustained-release tablet form containing pirfenidone and the application thereof in the regression of chronic renal failure, breast capsular contracture and liver fibrosis in humans. |
EP3225617A1 (en) * | 2012-02-16 | 2017-10-04 | Teva Pharmaceutical Industries Ltd | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
MX346763B (en) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne. |
MX356551B (en) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Antiseptic, antiseborrheic, exfoliating composition for getting rid of or preventing acne. |
AR092742A1 (en) | 2012-10-02 | 2015-04-29 | Intermune Inc | ANTIFIBROTIC PYRIDINONES |
KR101453688B1 (en) * | 2013-11-05 | 2014-11-04 | 포항공과대학교 산학협력단 | Method for fabricating light incident angle controlled electronic device |
NZ722927A (en) | 2014-01-10 | 2022-07-29 | Avalyn Pharma Inc | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
KR102373700B1 (en) | 2014-04-02 | 2022-03-11 | 인터뮨, 인크. | Anti-fibrotic pyridinones |
TWI745396B (en) | 2016-07-12 | 2021-11-11 | 日商鹽野義製藥股份有限公司 | Pharmaceutical composition for inhalation |
MX364040B (en) * | 2016-11-11 | 2019-04-11 | Cell Therapy And Tech S A De C V | Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash). |
EP3574906B1 (en) | 2017-01-30 | 2024-07-03 | Shionogi & Co., Ltd. | Solid preparation comprising quinazoline derivative |
KR20180100869A (en) * | 2017-03-02 | 2018-09-12 | 영진약품 주식회사 | Pharmaceutical composition of particle size controlled pirfenidone with improved compressibility and method for preparing the same |
CN109223723B (en) * | 2017-07-11 | 2021-08-27 | 南京华威医药科技集团有限公司 | Pirfenidone tablet and preparation method and application thereof |
MX366086B (en) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | A semi-solid topical composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage. |
TWI795462B (en) | 2017-11-17 | 2023-03-11 | 日商鹽野義製藥股份有限公司 | Pharmaceutical preparation excellent in light stability and dissolution property |
EP3511001B1 (en) | 2018-01-12 | 2021-09-22 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pirfenidone-containing tablet and capsule formulation |
PH12022552798A1 (en) * | 2020-04-22 | 2024-03-25 | Yungjin Pharmaceutical Co Ltd | Enteric-coated preparation comprising pirfenidone having improved safety and stability, and method for preparing same |
CN119630395A (en) | 2022-02-28 | 2025-03-14 | 努福米克斯技术有限公司 | Compositions and methods for treating idiopathic pulmonary fibrosis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3974281A (en) * | 1972-12-18 | 1976-08-10 | Affiliated Medical Research, Inc. | 5-Methyl-1-phenyl-2-(1H)-pyridone compositions and methods of use |
US6299904B1 (en) * | 1997-05-27 | 2001-10-09 | Takeda Chemical Industries, Ltd. | Solid pharmaceutical preparation |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4052509A (en) | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
US4042699A (en) | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
CA1261835A (en) | 1984-08-20 | 1989-09-26 | Masaaki Toda | (fused) benz(thio)amides |
US4753801A (en) * | 1985-10-25 | 1988-06-28 | Eli Lilly And Company | Sustained release tablets |
US5271946A (en) * | 1988-04-20 | 1993-12-21 | Asta Pharma Aktiengesellschaft | Controlled release azelastine-containing pharmaceutical compositions |
JPH02215719A (en) * | 1989-02-15 | 1990-08-28 | Yamauchi Akitomo | Agent for repairing fibrosing lesion tissue and preventing fibrosing lesion |
US5716632A (en) | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
US5310562A (en) * | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
US5518729A (en) | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
BR9406461A (en) | 1993-05-07 | 1996-01-30 | Solomon Begelfor Margolin | Compositions and methods for the repair and prevention of fibrotic lesions |
AU680019B2 (en) * | 1993-08-30 | 1997-07-17 | Warner-Lambert Company Llc | Tablet coating based on a melt-spun mixture of a saccharide and apolymer |
US5591766A (en) * | 1993-12-03 | 1997-01-07 | Cheil Foods & Chemicals, Inc. | Solid oral formulations of pyridone carboxylic acids |
US5639754A (en) | 1994-07-12 | 1997-06-17 | Janssen Pharmaceutica N.V. | Urea and thiourea derivatives of azolones |
MX9702531A (en) | 1994-10-07 | 1997-06-28 | Fujisawa Pharmaceutical Co | Cyclic hexapeptides having antibiotic activity. |
US6090822A (en) | 1995-03-03 | 2000-07-18 | Margolin; Solomon B. | Treatment of cytokine growth factor caused disorders |
JP3195361B2 (en) | 1995-06-21 | 2001-08-06 | 塩野義製薬株式会社 | Bicyclocyclic amino derivative and PGD2 antagonist containing the same |
JPH091787A (en) * | 1995-06-22 | 1997-01-07 | Canon Inc | Printing apparatus |
US5681382A (en) * | 1995-08-22 | 1997-10-28 | Shin-Etsu Chemical Co., Ltd. | Rapidly soluble coating composition and method for preparing same |
US5962478A (en) | 1995-09-19 | 1999-10-05 | Margolin; Solomon B. | Inhibition of tumor necrosis factor α |
CA2232191C (en) | 1995-09-19 | 2011-03-15 | Solomon B. Margolin | Inhibition of tumor necrosis factor alpha |
ATE241341T1 (en) * | 1997-09-10 | 2003-06-15 | Takeda Chemical Industries Ltd | STABILIZED PHARMACEUTICAL COMPOSITION |
PT1736144E (en) * | 1998-05-18 | 2016-02-10 | Takeda Pharmaceutical | Orally disintegrable tablets |
WO2001066551A2 (en) | 2000-03-07 | 2001-09-13 | Ranbaxy Laboratories Limited | Azole compounds as therapeutic agents for fungal infections |
CA2403594A1 (en) | 2000-03-27 | 2002-09-18 | Kyowa Hakko Kogyo Co., Ltd. | Granules having good taking property |
CN1443170A (en) | 2000-07-20 | 2003-09-17 | 神经原公司 | Capsaicin receptor ligands |
CA2423329A1 (en) | 2000-09-22 | 2003-03-20 | Takeda Chemical Industries, Ltd. | Solid preparations |
WO2002060446A1 (en) * | 2001-01-29 | 2002-08-08 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
JP4280073B2 (en) | 2001-04-12 | 2009-06-17 | ファーマコペイア ドラッグ ディスカバリー, インコーポレイテッド | Arylpiperidines and biarylpiperidines used as MCH antagonists |
JP4280074B2 (en) | 2001-04-25 | 2009-06-17 | 大正製薬株式会社 | Multiple unit type sustained release tablets |
EP1450801A4 (en) | 2001-11-27 | 2010-10-27 | Merck Sharp & Dohme | 2-AMINOQUINOLINE COMPOUNDS |
WO2003066595A2 (en) | 2002-02-01 | 2003-08-14 | Euro-Celtique S.A. | 2 - piperazine - pyridines useful for treating pain |
US6974818B2 (en) | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
ATE384698T1 (en) | 2002-06-28 | 2008-02-15 | Euro Celtique Sa | THERAPEUTIC PIPERAZINE DERIVATIVES FOR THE TREATMENT OF PAIN |
US7262194B2 (en) | 2002-07-26 | 2007-08-28 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
EP1539103A2 (en) | 2002-08-27 | 2005-06-15 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
US20060110358A1 (en) | 2002-08-28 | 2006-05-25 | Hsu Henry H | Combination therapy for treatment of fibrotic disorders |
US7157462B2 (en) | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
MXPA05003948A (en) | 2002-10-17 | 2005-06-17 | Amgen Inc | Benzimidazole derivatives and their use as vanilloid receptor ligands. |
US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
RS20050714A (en) | 2003-03-31 | 2008-04-04 | Pliva-Lachema A.S., | Pharmaceutical composition containing platinum co mplex as aktive substance and method of manufact uring thereof |
US20050008691A1 (en) | 2003-05-14 | 2005-01-13 | Arturo Siles Ortega | Bicalutamide compositions |
JP2007525188A (en) | 2003-05-16 | 2007-09-06 | インターミューン インコーポレイテッド | Synthetic chemokine receptor ligands and methods of use thereof |
WO2004103296A2 (en) | 2003-05-16 | 2004-12-02 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
AR044688A1 (en) | 2003-06-12 | 2005-09-21 | Euro Celtique Sa | USEFUL THERAPEUTIC AGENTS FOR THE TREATMENT OF PAIN |
JP2007527394A (en) | 2003-07-01 | 2007-09-27 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | Diffusion layer control solid |
CA2533515C (en) | 2003-07-24 | 2011-05-31 | Euro-Celtique S.A. | Heteroaryl-tetrahydropyridyl compounds useful for treating or preventing pain |
EA010852B1 (en) | 2003-07-24 | 2008-12-30 | Еуро-Селтик С. А. | Piperidine compounds and pharmaceutical compositions containing them |
PT1648880E (en) | 2003-08-01 | 2010-04-26 | Euro Celtique Sa | Therapeutic agents useful for treating pain |
PT1664016E (en) | 2003-09-22 | 2008-12-29 | Euro Celtique Sa | Therapeutic agents useful for treating pain |
CA2537010A1 (en) | 2003-09-22 | 2005-04-07 | Euro-Celtique S.A. | Phenyl - carboxamide compounds useful for treating pain |
US7407973B2 (en) | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
EP1683788B1 (en) | 2003-11-14 | 2012-03-21 | Shanghai Genomics, Inc. | Derivatives of pyridone and use thereof |
US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
DE602004019576D1 (en) | 2003-12-30 | 2009-04-02 | Euro Celtique Sa | FOR THE TREATMENT OF PAIN PIPERAZINE |
SE0400235D0 (en) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
US8642079B2 (en) | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
US7605176B2 (en) | 2004-03-06 | 2009-10-20 | Boehringer Ingelheim International Gmbh | β-ketoamide compounds with MCH antagonistic activity |
MY149038A (en) | 2004-05-26 | 2013-07-15 | Eisai R&D Man Co Ltd | Cinnamide compound |
US20090148407A1 (en) | 2005-07-25 | 2009-06-11 | Intermune, Inc. | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication |
NZ591443A (en) | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
WO2007069773A1 (en) | 2005-12-15 | 2007-06-21 | Shionogi & Co., Ltd. | A pharmaceutical composition comprising an amide derivative |
JP5372913B2 (en) | 2007-04-27 | 2013-12-18 | パーデュー、ファーマ、リミテッド、パートナーシップ | Effective treatment for pain |
US20090176796A1 (en) | 2007-04-27 | 2009-07-09 | Purdue Pharma L. P. | Trpv1 antagonists including amide substituent and uses thereof |
EP2276734A1 (en) | 2008-04-17 | 2011-01-26 | Pfizer Inc. | 4-benzylidene-3-methylpiperidine aryl carboxamide compounds useful as faah inhibitors |
CA2725933C (en) | 2008-06-05 | 2018-01-16 | Janssen Pharmaceutica Nv | Drug combinations comprising a dgat inhibitor and a ppar-agonist |
US8546388B2 (en) | 2008-10-24 | 2013-10-01 | Purdue Pharma L.P. | Heterocyclic TRPV1 receptor ligands |
US8703962B2 (en) | 2008-10-24 | 2014-04-22 | Purdue Pharma L.P. | Monocyclic compounds and their use as TRPV1 ligands |
US8759362B2 (en) | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
WO2011162409A1 (en) | 2010-06-22 | 2011-12-29 | Shionogi & Co., Ltd. | Compounds having trpv1 antagonistic activity and uses thereof |
-
2002
- 2002-01-25 WO PCT/JP2002/000544 patent/WO2002060446A1/en active Application Filing
- 2002-01-25 JP JP2002560638A patent/JP4077320B2/en not_active Expired - Fee Related
- 2002-01-25 EP EP02710352A patent/EP1356816B1/en not_active Expired - Lifetime
- 2002-01-25 AT AT02710352T patent/ATE452637T1/en not_active IP Right Cessation
- 2002-01-25 DE DE60234812T patent/DE60234812D1/en not_active Expired - Lifetime
- 2002-01-25 KR KR1020037009856A patent/KR100777169B1/en not_active Expired - Lifetime
- 2002-01-25 US US10/470,334 patent/US7867516B2/en not_active Expired - Lifetime
- 2002-01-25 KR KR1020077018953A patent/KR100891887B1/en not_active Expired - Lifetime
- 2002-01-29 TW TW091101440A patent/TWI314868B/en not_active IP Right Cessation
-
2010
- 2010-11-08 US US12/941,994 patent/US20110104276A1/en not_active Abandoned
-
2011
- 2011-12-21 US US13/333,142 patent/US20120183615A1/en not_active Abandoned
-
2012
- 2012-10-26 US US13/662,221 patent/US9017722B2/en not_active Expired - Fee Related
-
2015
- 2015-03-27 US US14/671,251 patent/US20150209341A1/en not_active Abandoned
- 2015-11-24 US US14/951,313 patent/US9561217B2/en not_active Expired - Fee Related
-
2016
- 2016-12-20 US US15/385,451 patent/US20170100380A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3974281A (en) * | 1972-12-18 | 1976-08-10 | Affiliated Medical Research, Inc. | 5-Methyl-1-phenyl-2-(1H)-pyridone compositions and methods of use |
US6299904B1 (en) * | 1997-05-27 | 2001-10-09 | Takeda Chemical Industries, Ltd. | Solid pharmaceutical preparation |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9561217B2 (en) | 2001-01-29 | 2017-02-07 | Intermune, Inc. | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
US8753679B2 (en) | 2005-09-22 | 2014-06-17 | Intermune, Inc. | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
US10188637B2 (en) | 2016-03-29 | 2019-01-29 | Hoffmann-La Roche Inc. | Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same |
Also Published As
Publication number | Publication date |
---|---|
ATE452637T1 (en) | 2010-01-15 |
US9561217B2 (en) | 2017-02-07 |
JP4077320B2 (en) | 2008-04-16 |
US20150209341A1 (en) | 2015-07-30 |
US20170100380A1 (en) | 2017-04-13 |
WO2002060446A1 (en) | 2002-08-08 |
DE60234812D1 (en) | 2010-02-04 |
US20130115288A1 (en) | 2013-05-09 |
US20160074375A1 (en) | 2016-03-17 |
JPWO2002060446A1 (en) | 2004-05-27 |
EP1356816A4 (en) | 2005-02-09 |
KR100777169B1 (en) | 2007-11-16 |
US20120183615A1 (en) | 2012-07-19 |
KR20030072608A (en) | 2003-09-15 |
TWI314868B (en) | 2009-09-21 |
EP1356816A1 (en) | 2003-10-29 |
US7867516B2 (en) | 2011-01-11 |
US9017722B2 (en) | 2015-04-28 |
KR20070093006A (en) | 2007-09-14 |
US20040048902A1 (en) | 2004-03-11 |
KR100891887B1 (en) | 2009-04-03 |
EP1356816B1 (en) | 2009-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9561217B2 (en) | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone | |
EP0749308B1 (en) | Film coated tablet of paracetamol and domperidone | |
US20060153925A1 (en) | Novel solid pharmaceutical composition comprising amisulpride | |
JP2009256344A (en) | Coated particulate containing proton pump inhibitor | |
KR20030097892A (en) | Drug preparations | |
RU2600831C2 (en) | Oral administrable pharmaceutical composition | |
KR100846945B1 (en) | Swallowing tablets containing paracetamol | |
JP7571394B2 (en) | Orally disintegrating tablets containing edoxaban | |
US20210244730A1 (en) | Pharmaceutical composition containing an antitumor agent | |
SK106094A3 (en) | Pharmaceutical agent | |
US20140343076A1 (en) | Pharmaceutical compositions of lurasidone | |
WO2010087358A1 (en) | Novel composition | |
KR20030081027A (en) | Coated solid preparation having hypnotic action | |
JP6328138B2 (en) | Of N- [5- [2- (3,5-dimethoxyphenyl) ethyl] -2H-pyrazol-3-yl] -4-[(3R, 5S) -3,5-dimethylpiperazin-1-yl] benzamide Pharmaceutical formulation | |
KR20040091135A (en) | Tablet containing pilsicainide hydrochloride(dry) | |
WO2020209350A1 (en) | Rapid disintegrating oral tablet for treatment of diabetes | |
JP2019210262A (en) | Orally disintegrating tablet | |
EP4413987A1 (en) | Antifibrotic composition | |
KR102488167B1 (en) | Solid composition of pyrrole carboxamide | |
JP2024077150A (en) | tablet | |
JP2024033173A (en) | Pharmaceutical compositions and pharmaceutical formulations | |
CN115804774A (en) | Oxagolide pharmaceutical composition, pharmaceutical preparation containing same and application of pharmaceutical composition | |
WO2019199136A1 (en) | Lenalidomide oral tablet composition enabling enhanced disintegration | |
KR20200002486A (en) | Wet granulation composition, tablet comprising same, and method for preparing the tablet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: INTERMUNE, INC., CALIFORNIA Free format text: CERTIFICATE OF CHANGE OF COMPANY'S ADDRESS;ASSIGNOR:INTERMUNE, INC.;REEL/FRAME:046638/0466 Effective date: 20180711 |